{"protocolSection":{"identificationModule":{"nctId":"NCT00536471","orgStudyIdInfo":{"id":"11669"},"secondaryIdInfos":[{"id":"F1J-US-HMFS"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients","officialTitle":"Duloxetine Versus Placebo in Patients With Major Depressive Disorder (MDD): Assessment of Energy and Vitality in MDD"},"statusModule":{"statusVerifiedDate":"2009-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-09"},"primaryCompletionDateStruct":{"date":"2008-05","type":"ACTUAL"},"completionDateStruct":{"date":"2008-12","type":"ACTUAL"},"studyFirstSubmitDate":"2007-09-25","studyFirstSubmitQcDate":"2007-09-25","studyFirstPostDateStruct":{"date":"2007-09-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-05-28","resultsFirstSubmitQcDate":"2009-05-28","resultsFirstPostDateStruct":{"date":"2009-07-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-11-17","lastUpdatePostDateStruct":{"date":"2009-11-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb). The purpose of this study is to compare the efficacy and safety of Duloxetine 60 milligrams (mg) once daily to placebo on depression in patients aged 18-65. Data from the two trials will be reported in both individual and pooled analyses. Pooling the two studies will allow for increased power to detect differences between duloxetine and placebo on secondary and exploratory objectives. Only one data lock is planned for this study, when all patients have completed all study procedures."},"conditionsModule":{"conditions":["Major Depressive Disorder"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":776,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A","type":"EXPERIMENTAL","description":"duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months","interventionNames":["Drug: Duloxetine hydrochloride"]},{"label":"B","type":"PLACEBO_COMPARATOR","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Duloxetine hydrochloride","armGroupLabels":["A"],"otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline to 8 Weeks in 24-Item Hamilton Depression Rating Scale (HAMD-24) Item 7 (Work and Activities)","description":"Item 7 of the HAMD-24 assesses loss of interest or pleasure in work and activities and is an essential symptom in MDD. Scores range from 0 (no difficulty/no loss) to 4 (difficulty/loss).","timeFrame":"baseline, 8 weeks"}],"secondaryOutcomes":[{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in the 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score and HAMD-24 Subscales (8 Week Endpoint for Maier Subscale)","description":"The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe). Please see baseline demographics for subscale total scores.","timeFrame":"Baseline, 8 weeks, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Total Score","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Item 1:Depressed Mood","description":"Measures depressed mood on a scale of 0 (absent) to 4 (very depressed).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 2:Feelings of Guilt","description":"Measures feelings of guilt on a scale of 0 (absent) to 4 (very guilty).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 3:Suicide","description":"Measures thoughts of suicide on a scale of 0 (absent) to 4 (attempts suicide).","timeFrame":"Baseline, 12 weeks, 9 Months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 4:Insomnia Early","description":"Measures early insomnia on a scale of 0 (no difficulty falling asleep) to 2 (complains of nightly difficulty falling asleep).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 5:Insomnia Middle","description":"Measures middle insomnia on a scale of 0 (no difficulty) to 2 (waking during the night).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 6:Insomnia Late","description":"Measures late insomnia on a scale of 0 (no difficulty) to 2 (unable to fall asleep again if gets out of bed).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 9 Month Endpoint in HAMD-24 - Item 7:Work and Activities","description":"Item 7 of the HAMD-24 assesses loss of interest or pleasure in work and activities and is an essential symptom in MDD. Scores range from 0 (no difficulty/no loss) to 4 (difficulty/loss).","timeFrame":"Baseline, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 8:Retardation","description":"Measures slowness of thought and speech; impaired ability to concentrate; decreased motor activity on a scale of 0 (normal speech and thought) to 4 (complete stupor).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 9:Agitation","description":"Measures agitation on a scale of 0 (none) to 4 (hand-wringing, nail-biting)","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 10:Anxiety (Psychic)","description":"Measures anxiety on a scale of 0 (no difficulty) to 4 (fears expressed)","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 11:Anxiety (Somatic)","description":"Measures physiological concomitants of anxiety on a scale of 0 (absent) to 4 (incapacitating).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 12:Somatic Symptoms/Gastrointestinal","description":"Measures gastrointestical somatic symptoms on a scale of 0 (none) to 2 (difficulty eating, requires medication for symptoms).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 13:Somatic Symptoms/General","description":"Measures general somatic symptoms on a scale of 0 (none) to 2 (any clear-cut symptoms).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 14:Genital Symptoms","description":"Measures genital symptoms (loss of libido, menstrual disturbances) on a scale of 0 (absent) to 2 (severe).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 15:Hypochondriasis","description":"Measures hypochondriasis on a scale of 0 (not present) to 4 (hypochondriacal delusions).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 16:Loss of Weight","description":"Measures weight loss since last visit on a scale of 0 (no weight loss) to 2 (definite weight loss caused by present illness).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 17:Insight","description":"Measures insight on a scale of 0 (acknowledges being depressed and ill) to 2 (denies being ill at all).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18A:Diurnal Variation","description":"Measures whether symptoms are worse in morning or evening on a scale of 0 (no variation), 1 (worse in morning), or 2 (worse in evening).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18B:Diurnal Variation-Severity","description":"Measures the severity of the diurnal variation on a scale of 0 (none) to 2 (severe).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 19: Depersonalization and Derealization","description":"Measures feelings of unreality on a scale of 0 (absent) to 4 (incapacitating).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 20:Paranoid Symptoms","description":"Measures paranoid symptoms on a scale of 0 (none) to 2 (severe).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 21:Obsessional and Compulsive Symptoms","description":"Measures obsessional and compulsive symptoms on a scale of 0 (absent) to 2 (severe).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 22B:Helplessness","description":"Measures feelings of helplessness on a scale of 0 (absent) to 4 (severe).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 23B:Hopelessness","description":"Measures feelings of hopelessness on a scale of 0 (absent) to 4 (expresses feelings of discouragement, despair, and/or pessimism about the future which cannot be dispelled).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 24B:Worthlessness","description":"Measures feelings of worthlessness on a scale of 0 (absent) to 4 (severe).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment).","description":"The 30-item BPOMS measures mood states and has 6 factors: tension-anxiety, depression-dejection, anxiety-hostility, fatigue, confusion, and vigor. Item scores: 0 (not at all) to 4 (extremely). Each factor scores range from 0 to 20. The Total score is sum of all factor scores minus the factor score for vigor (Total=Ten+Dep+Ang+Fat+Con-Vig).","timeFrame":"Baseline, 12 weeks"},{"measure":"Change From Baseline to 9 Month Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment)","description":"The 30-item BPOMS measures mood states and has 6 factors: tension-anxiety, depression-dejection, anxiety-hostility, fatigue, confusion, and vigor. Item scores: 0 (not at all) to 4 (extremely). Each factor scores range from 0 to 20. The Total score is sum of all factor scores minus the factor score for vigor (Total=Ten+Dep+Ang+Fat+Con-Vig).","timeFrame":"Baseline, 9 months"},{"measure":"Change From Baseline to 12 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores","description":"The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Individual item scores range from 0 to 10. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life.","timeFrame":"Baseline, 12 weeks"},{"measure":"Change From Baseline to 9 Month Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores","description":"The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Individual item scores range from 0 to 10. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life.","timeFrame":"Baseline, 9 months"},{"measure":"Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7","description":"Relative contribution of improvement on the mood states, defined by BPOMS total score (calculated from subscales) to overall improvement in work and activities, HAMD-24 item 7 using path analysis.","timeFrame":"Over 12 weeks"},{"measure":"Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7 - Percent of Total Effect","description":"For Group A, at least one effect was in the opposite direction, percent of total effect was not calculated.","timeFrame":"over 12 weeks"},{"measure":"Path Analysis of BPOMS Total Score to Overall Improvement in Sheehan Disability Scale (SDS) Total Score","description":"Relative contribution of improvement on the mood states, defined by BPOMS total score (determined from subscales) to overall improvement in SDS total score using path analysis.","timeFrame":"over 12 weeks"},{"measure":"Path Analysis of BPOMS Total Score to Overall Improvement in SDS Total Score - Percent of Total Effect","description":"For Group A, at least one effect was in the opposite direction, percent of total effect was not calculated.","timeFrame":"Over 12 weeks"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) Total Score","description":"A 16-item patient-rated measure of depressive symptomatology. The total score ranges from 0 to 27 with higher scores indicative of greater severity.","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Probability of Remission at 12 Week Endpoint and Sustained Remission at 9 Month Endpoint","description":"Probability of remission as measured by the HAMD17 Total Score ≤ 7 and by the QIDS16SR Total Score ≤ 5. The visitwise percentages of patients meeting criteria in the Acute Therapy Phase for remission (visitwise binary outcome, yes/no) will be analyzed using a categorical, pseudo-likelihood-based repeated measures approach. This analysis will include the fixed, categorical effects of treatment, investigator, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline score.","timeFrame":"12 weeks, 9 months"},{"measure":"Probability of Response at 12 Week Endpoint","description":"Probability of response as measured by ≥ 50% Improvement in the HAMD17 Total Score and ≥ 50% Improvement in the QIDS16SR Total Score. The visitwise percentages of patients meeting criteria in the Acute Therapy Phase for response (visitwise binary outcome, yes/no) will be analyzed using a categorical, pseudo-likelihood-based repeated measures approach. This analysis will include the fixed, categorical effects of treatment, investigator, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline score.","timeFrame":"12 weeks"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in Pain Numerical Rating Scale (NRS)","description":"Item 1=Average musculoskeletal pain severity over the last week as measured by an 11-point Likert scale. Scores range from 0 (no pain) to 10 (worst possible pain). Item 7=How much they have been bothered by pain over the last week. Scores range from 0 (not bothered at all)to 10 (extremely bothered).","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoint in the Clinical Global Impression-Severity Scale (CGI-S)","description":"Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ)","description":"A 7-item patitent-rated questionnaire pertaining to a patient's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each of the 7 questions is scored on a 6-point scale ranging fom 1 (greater than normal) to 6 (totally absent). Total score ranges from 7 to 42.","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in the Social Adaptation Self-evaluation Scale (SASS) Total Score","description":"A 21-item self-rated scale that evaluates patient social motivation and behavior in depression. Each of the 21 items is scored from 0 (minimal social adjustment) to 3 (maximal social adjustment). Total score ranges from 0 to 60.","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in Blood Pressure","description":"Sitting systolic and diastolic blood pressure.","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in Pulse Rate","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Change From Baseline to 12 Week and 9 Month Endpoints in Weight","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Abnormal Vital Signs at Anytime Over 12 Weeks","timeFrame":"over 12 weeks"},{"measure":"Abnormal Vital Signs at Anytime Over 9 Months","timeFrame":"over 9 months"},{"measure":"Abnormal Vital Signs at 12 Week Endpoint","timeFrame":"12 weeks"},{"measure":"Abnormal Vital Signs at 9 Month Endpoint","timeFrame":"9 months"},{"measure":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Bilirubin, Creatinine, Uric Acid","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Hematocrit","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Mean Cell Volume (MCV)","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Platelet Count","timeFrame":"Baseline, 12 weeks, 9 months"},{"measure":"Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Alkaline Phosphatase","timeFrame":"baseline, 9 months"},{"measure":"Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Hemoglobin","timeFrame":"Baseline, 9 months"},{"measure":"Statistically Significant Abnormal Laboratory Values at Anytime/12 Week Endpoint","description":"The number of participants with statistically significant abnormal lab values at anytime and at 12 week endpoint were the same.","timeFrame":"over 3 months"},{"measure":"Statistically Significant Abnormal Laboratory Values at Anytime During 9 Months","timeFrame":"over 9 months"},{"measure":"Statistically Significant Abnormal Laboratory Values at 9 Month Endpoint","timeFrame":"9 months"},{"measure":"Summary of Adverse Events Leading to Discontinuation","timeFrame":"over 9 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female outpatients\n* Aged 18-65 who meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder (MDD)\n* Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score of at least 22 at visits 1 and 2\n* Have a Clinical Global Impressions of Severity Scale (CGI-S) score of at least 4 at visits 1 and 2\n* Have a degree of understanding such that the patient can provide informed consent, complete protocol required assessments and communicate intelligibly with the investigator and study coordinator.\n\nExclusion Criteria:\n\n* Patients judged clinically to be at serious suicidal risk in the opinion of the investigator\n* Patients who have any prior history of bipolar disorder, psychosis, or schizophrenia\n* Patients who have any current (within the past six months) DSM-IV-TR primary Axis I disorder other than MDD\n* Patients with uncontrolled narrow-angle glaucoma\n* Patients who have a serious medical illness that is in the opinion of the investigator not stabilized or is likely to require intervention, hospitalization, or use of an excluded medication during the course of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beverly Hills","state":"California","zip":"90210","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Escondido","state":"California","zip":"92025","country":"United States","geoPoint":{"lat":33.11921,"lon":-117.08642}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"National City","state":"California","zip":"91950","country":"United States","geoPoint":{"lat":32.67811,"lon":-117.0992}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hamden","state":"Connecticut","zip":"06518","country":"United States","geoPoint":{"lat":41.39593,"lon":-72.89677}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New Britain","state":"Connecticut","zip":"06050","country":"United States","geoPoint":{"lat":41.66121,"lon":-72.77954}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New London","state":"Connecticut","zip":"06320","country":"United States","geoPoint":{"lat":41.35565,"lon":-72.09952}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wilmington","state":"Delaware","zip":"19808","country":"United States","geoPoint":{"lat":39.74595,"lon":-75.54659}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Washington D.C.","state":"District of Columbia","zip":"20037","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bradenton","state":"Florida","zip":"34208","country":"United States","geoPoint":{"lat":27.49893,"lon":-82.57482}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fort Myers","state":"Florida","zip":"33912","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gainesville","state":"Florida","zip":"32606","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Maitland","state":"Florida","zip":"32751","country":"United States","geoPoint":{"lat":28.62778,"lon":-81.36312}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Atlanta","state":"Georgia","zip":"30328","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Edwardsville","state":"Illinois","zip":"62025","country":"United States","geoPoint":{"lat":38.81144,"lon":-89.95316}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hoffman Estates","state":"Illinois","zip":"60169","country":"United States","geoPoint":{"lat":42.04281,"lon":-88.0798}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Naperville","state":"Illinois","zip":"60540","country":"United States","geoPoint":{"lat":41.78586,"lon":-88.14729}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Oak Brook","state":"Illinois","zip":"60523","country":"United States","geoPoint":{"lat":41.83281,"lon":-87.92895}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lafayette","state":"Indiana","zip":"47905","country":"United States","geoPoint":{"lat":40.4167,"lon":-86.87529}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Terre Haute","state":"Indiana","zip":"47802","country":"United States","geoPoint":{"lat":39.4667,"lon":-87.41391}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Prairie Village","state":"Kansas","zip":"66206","country":"United States","geoPoint":{"lat":38.99167,"lon":-94.63357}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Baltimore","state":"Maryland","zip":"21285","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Glen Burnie","state":"Maryland","zip":"21061","country":"United States","geoPoint":{"lat":39.16261,"lon":-76.62469}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rockville","state":"Maryland","zip":"20852","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Belmont","state":"Massachusetts","zip":"02478","country":"United States","geoPoint":{"lat":42.39593,"lon":-71.17867}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pittsfield","state":"Massachusetts","zip":"01201","country":"United States","geoPoint":{"lat":42.45008,"lon":-73.24538}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Chesterfield","state":"Missouri","zip":"63017","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"City of Saint Peters","state":"Missouri","zip":"63376","country":"United States","geoPoint":{"lat":38.80033,"lon":-90.62651}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Clementon","state":"New Jersey","zip":"08021","country":"United States","geoPoint":{"lat":39.8115,"lon":-74.98294}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cedarhurst","state":"New York","zip":"11516","country":"United States","geoPoint":{"lat":40.62288,"lon":-73.7243}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"New York","state":"New York","zip":"10021","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Olean","state":"New York","zip":"14760","country":"United States","geoPoint":{"lat":42.07756,"lon":-78.42974}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Staten Island","state":"New York","zip":"10305","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Allentown","state":"Pennsylvania","zip":"18104","country":"United States","geoPoint":{"lat":40.60843,"lon":-75.49018}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Media","state":"Pennsylvania","zip":"19063","country":"United States","geoPoint":{"lat":39.91678,"lon":-75.38769}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lake Jackson","state":"Texas","zip":"77566","country":"United States","geoPoint":{"lat":29.03386,"lon":-95.43439}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Arlington","state":"Virginia","zip":"22201","country":"United States","geoPoint":{"lat":38.88101,"lon":-77.10428}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charlottesville","state":"Virginia","zip":"22903","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Richmond","state":"Virginia","zip":"23230","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Brown Deer","state":"Wisconsin","zip":"53223","country":"United States","geoPoint":{"lat":43.16334,"lon":-87.96453}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"West Allis","state":"Wisconsin","zip":"53227","country":"United States","geoPoint":{"lat":43.01668,"lon":-88.00703}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Arecibo","zip":"00612","country":"Puerto Rico","geoPoint":{"lat":18.47245,"lon":-66.71573}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Caguas","zip":"00725","country":"Puerto Rico","geoPoint":{"lat":18.23412,"lon":-66.0485}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ponce","zip":"00731","country":"Puerto Rico","geoPoint":{"lat":18.01031,"lon":-66.62398}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"San Juan","zip":"00907","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}}]},"referencesModule":{"references":[{"pmid":"25980552","type":"DERIVED","citation":"Harada E, Kato M, Fujikoshi S, Wohlreich MM, Berggren L, Tokuoka H. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials. Int J Clin Pract. 2015 Oct;69(10):1139-48. doi: 10.1111/ijcp.12658. Epub 2015 May 16."},{"pmid":"25080392","type":"DERIVED","citation":"Dodd S, Berk M, Kelin K, Zhang Q, Eriksson E, Deberdt W, Craig Nelson J. Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. J Affect Disord. 2014 Oct;168:284-93. doi: 10.1016/j.jad.2014.05.014. Epub 2014 Jun 4."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Study HMFS comprises two identical trials (identified as Group A and Group B). Study Period I was a screening period. Study Period II was a 9-month double-blind treatment period. Study Period III was an optional double-blind 2-week discontinuation/taper period.","groups":[{"id":"FG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"FG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"FG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"FG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"257"},{"groupId":"FG001","numSubjects":"127"},{"groupId":"FG002","numSubjects":"261"},{"groupId":"FG003","numSubjects":"131"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"43"},{"groupId":"FG002","numSubjects":"122"},{"groupId":"FG003","numSubjects":"57"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"84"},{"groupId":"FG002","numSubjects":"139"},{"groupId":"FG003","numSubjects":"74"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"48"},{"groupId":"FG003","numSubjects":"22"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"28"},{"groupId":"FG003","numSubjects":"13"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"43"},{"groupId":"FG003","numSubjects":"21"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"9"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"BG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"BG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"BG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"257"},{"groupId":"BG001","value":"127"},{"groupId":"BG002","value":"261"},{"groupId":"BG003","value":"131"},{"groupId":"BG004","value":"776"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42.2","spread":"12.2"},{"groupId":"BG001","value":"43.7","spread":"12.5"},{"groupId":"BG002","value":"44.7","spread":"12.2"},{"groupId":"BG003","value":"43.9","spread":"11.9"},{"groupId":"BG004","value":"43.6","spread":"12.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"169"},{"groupId":"BG003","value":"87"},{"groupId":"BG004","value":"489"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"92"},{"groupId":"BG003","value":"44"},{"groupId":"BG004","value":"287"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"222"},{"groupId":"BG003","value":"110"},{"groupId":"BG004","value":"704"}]}]},{"title":"Puerto Rico","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"39"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"72"}]}]}]},{"title":"History - Atypical Depression","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"38"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"250"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"242"},{"groupId":"BG003","value":"124"},{"groupId":"BG004","value":"738"}]}]}]},{"title":"History - Melancholic Depression","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"134"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"147"},{"groupId":"BG003","value":"71"},{"groupId":"BG004","value":"423"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"114"},{"groupId":"BG003","value":"60"},{"groupId":"BG004","value":"353"}]}]}]},{"title":"History - Seasonal Pattern in Major Depressive Disorder (MDD) if ≥3 Previous MDD Episodes","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"19"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"220"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"232"},{"groupId":"BG003","value":"112"},{"groupId":"BG004","value":"669"}]}]},{"title":"Missing Response","categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"88"}]}]}]},{"title":"Race/Ethnicity","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"16"},{"groupId":"BG004","value":"145"}]}]},{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"160"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"172"},{"groupId":"BG003","value":"81"},{"groupId":"BG004","value":"486"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"30"},{"groupId":"BG004","value":"125"}]}]},{"title":"East Asian","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"12"}]}]},{"title":"West Asian (Indian sub-continent)","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"7"}]}]},{"title":"Native American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Body Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"centimeters","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"168.1","spread":"10.1"},{"groupId":"BG001","value":"168.5","spread":"9.2"},{"groupId":"BG002","value":"169.0","spread":"9.7"},{"groupId":"BG003","value":"168.8","spread":"9.4"},{"groupId":"BG004","value":"168.6","spread":"9.7"}]}]}]},{"title":"Body Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilograms","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"88.8","spread":"23.7"},{"groupId":"BG001","value":"84.9","spread":"22.5"},{"groupId":"BG002","value":"88.6","spread":"26.6"},{"groupId":"BG003","value":"86.4","spread":"23.5"},{"groupId":"BG004","value":"87.7","spread":"24.5"}]}]}]},{"title":"Evaluation - Brief Profile of Mood States (BPOMS)","description":"The 30-item BPOMS measures mood states and has 6 factors: tension-anxiety, depression-dejection, anxiety-hostility, fatigue, confusion, and vigor. Item scores: 0 (not at all) to 4 (extremely). Each factor scores range from 0 to 20. The Total score is sum of all factor scores minus the factor score for vigor (Total=Ten+Dep+Ang+Fat+Con-Vig).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"title":"Total Score","categories":[{"measurements":[{"groupId":"BG000","value":"49.0","spread":"19.2"},{"groupId":"BG001","value":"47.5","spread":"18.7"},{"groupId":"BG002","value":"51.8","spread":"19.3"},{"groupId":"BG003","value":"51.8","spread":"18.7"},{"groupId":"BG004","value":"50.2","spread":"19.1"}]}]},{"title":"Tension-Anxiety Score","categories":[{"measurements":[{"groupId":"BG000","value":"9.5","spread":"4.6"},{"groupId":"BG001","value":"9.2","spread":"4.6"},{"groupId":"BG002","value":"10.0","spread":"5.0"},{"groupId":"BG003","value":"10.4","spread":"4.6"},{"groupId":"BG004","value":"9.8","spread":"4.7"}]}]},{"title":"Depression-Dejection Score","categories":[{"measurements":[{"groupId":"BG000","value":"11.8","spread":"4.8"},{"groupId":"BG001","value":"11.5","spread":"4.8"},{"groupId":"BG002","value":"12.3","spread":"4.6"},{"groupId":"BG003","value":"12.0","spread":"4.2"},{"groupId":"BG004","value":"12.0","spread":"4.7"}]}]},{"title":"Anger-Hostility Score","categories":[{"measurements":[{"groupId":"BG000","value":"8.9","spread":"5.4"},{"groupId":"BG001","value":"9.0","spread":"5.4"},{"groupId":"BG002","value":"9.5","spread":"5.1"},{"groupId":"BG003","value":"9.5","spread":"5.4"},{"groupId":"BG004","value":"9.2","spread":"5.3"}]}]},{"title":"Vigor-Activity Score","categories":[{"measurements":[{"groupId":"BG000","value":"3.4","spread":"3.1"},{"groupId":"BG001","value":"3.9","spread":"3.1"},{"groupId":"BG002","value":"3.6","spread":"3.5"},{"groupId":"BG003","value":"3.4","spread":"3.0"},{"groupId":"BG004","value":"3.5","spread":"3.2"}]}]},{"title":"Fatigue-Inertia Score","categories":[{"measurements":[{"groupId":"BG000","value":"12.8","spread":"4.6"},{"groupId":"BG001","value":"12.3","spread":"4.8"},{"groupId":"BG002","value":"13.5","spread":"4.7"},{"groupId":"BG003","value":"13.2","spread":"4.5"},{"groupId":"BG004","value":"13.0","spread":"4.7"}]}]},{"title":"Confusion-Bewilderment Score","categories":[{"measurements":[{"groupId":"BG000","value":"9.7","spread":"4.0"},{"groupId":"BG001","value":"9.6","spread":"3.9"},{"groupId":"BG002","value":"9.8","spread":"4.1"},{"groupId":"BG003","value":"10.1","spread":"3.8"},{"groupId":"BG004","value":"9.8","spread":"4.0"}]}]}]},{"title":"Evaluation - 16-Item Quick Inventory of Depressive Symptomatology (QIDS16) Total Score","description":"A 16-item patient-rated measure of depressive symptomatology. The total score ranges from 0 to 27 with higher scores indicative of greater severity.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14.7","spread":"4.1"},{"groupId":"BG001","value":"13.7","spread":"4.4"},{"groupId":"BG002","value":"15.0","spread":"4.4"},{"groupId":"BG003","value":"14.7","spread":"3.8"},{"groupId":"BG004","value":"14.6","spread":"4.2"}]}]}]},{"title":"Evaluation - 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score","description":"The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22.9","spread":"4.3"},{"groupId":"BG001","value":"22.8","spread":"3.7"},{"groupId":"BG002","value":"22.8","spread":"4.5"},{"groupId":"BG003","value":"22.9","spread":"4.9"},{"groupId":"BG004","value":"22.8","spread":"4.4"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 10:Anxiety (Psychic)","description":"Measures anxiety on a scale of 0 (no difficulty) to 4 (fears expressed).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2.1","spread":"0.8"},{"groupId":"BG001","value":"2.1","spread":"0.7"},{"groupId":"BG002","value":"2.1","spread":"0.8"},{"groupId":"BG003","value":"2.2","spread":"0.8"},{"groupId":"BG004","value":"2.1","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 11:Anxiety (Somatic)","description":"Measures physiological concomitants of anxiety on a scale of 0 (absent) to 4 (incapacitating).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.4","spread":"0.8"},{"groupId":"BG001","value":"1.5","spread":"0.8"},{"groupId":"BG002","value":"1.6","spread":"0.9"},{"groupId":"BG003","value":"1.6","spread":"0.9"},{"groupId":"BG004","value":"1.5","spread":"0.9"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 13:Somatic Symptoms/General","description":"Measures general somatic symptoms on a scale of 0 (none) to 2 (any clear-cut symptoms).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.6","spread":"0.6"},{"groupId":"BG001","value":"1.7","spread":"0.5"},{"groupId":"BG002","value":"1.7","spread":"0.5"},{"groupId":"BG003","value":"1.7","spread":"0.6"},{"groupId":"BG004","value":"1.7","spread":"0.5"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 14:Genital Symptoms","description":"Measures genital symptoms (loss of libido, menstrual disturbances) on a scale of 0 (absent) to 2 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.3","spread":"0.8"},{"groupId":"BG001","value":"1.2","spread":"0.9"},{"groupId":"BG002","value":"1.3","spread":"0.8"},{"groupId":"BG003","value":"1.1","spread":"0.9"},{"groupId":"BG004","value":"1.2","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 15:Hypochondriasis","description":"Measures hypochondriasis on a scale of 0 (not present) to 4 (hypochondriacal delusions).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.7","spread":"0.8"},{"groupId":"BG001","value":"0.7","spread":"0.8"},{"groupId":"BG002","value":"1.0","spread":"0.9"},{"groupId":"BG003","value":"1.1","spread":"0.9"},{"groupId":"BG004","value":"0.9","spread":"0.9"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 16:Loss of Weight","description":"Measures weight loss since last visit on a scale of 0 (no weight loss) to 2 (definite weight loss caused by present illness).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.3","spread":"0.6"},{"groupId":"BG001","value":"0.2","spread":"0.5"},{"groupId":"BG002","value":"0.3","spread":"0.6"},{"groupId":"BG003","value":"0.4","spread":"0.7"},{"groupId":"BG004","value":"0.3","spread":"0.6"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 17:Insight","description":"Measures insight on a scale of 0 (acknowledges being depressed and ill) to 2 (denies being ill at all).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.2","spread":"0.4"},{"groupId":"BG001","value":"0.2","spread":"0.4"},{"groupId":"BG002","value":"0.1","spread":"0.2"},{"groupId":"BG003","value":"0.0","spread":"0.2"},{"groupId":"BG004","value":"0.1","spread":"0.4"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 18A:Diurnal Variation","description":"Measures whether symptoms are worse in morning or evening on a scale of 0 (no variation), 1 (worse in morning), or 2 (worse in evening).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.8","spread":"0.8"},{"groupId":"BG001","value":"0.9","spread":"0.9"},{"groupId":"BG002","value":"1.0","spread":"0.9"},{"groupId":"BG003","value":"1.0","spread":"0.9"},{"groupId":"BG004","value":"0.9","spread":"0.9"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 1:Depressed Mood","description":"Measures depressed mood on a scale of 0 (absent) to 4 (very depressed).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3.0","spread":"0.6"},{"groupId":"BG001","value":"2.9","spread":"0.6"},{"groupId":"BG002","value":"2.9","spread":"0.6"},{"groupId":"BG003","value":"2.9","spread":"0.5"},{"groupId":"BG004","value":"2.9","spread":"0.6"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 20:Paranoid Symptoms","description":"Measures paranoid symptoms on a scale of 0 (none) to 3 (delusions of reference and persecution).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.2","spread":"0.5"},{"groupId":"BG001","value":"0.2","spread":"0.5"},{"groupId":"BG002","value":"0.2","spread":"0.5"},{"groupId":"BG003","value":"0.2","spread":"0.4"},{"groupId":"BG004","value":"0.2","spread":"0.5"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 22B:Helplessness","description":"Measures feelings of helplessness on a scale of 0 (absent) to 4 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.4","spread":"1.0"},{"groupId":"BG001","value":"1.5","spread":"1.0"},{"groupId":"BG002","value":"1.5","spread":"1.0"},{"groupId":"BG003","value":"1.7","spread":"1.0"},{"groupId":"BG004","value":"1.5","spread":"1.0"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 23B:Hopelessness","description":"Measures feelings of hopelessness on a scale of 0 (absent) to 3 (expresses feelings of discouragement, despair, and/or pessimism about the future which cannot be dispelled).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.3","spread":"0.8"},{"groupId":"BG001","value":"1.3","spread":"0.9"},{"groupId":"BG002","value":"1.3","spread":"0.8"},{"groupId":"BG003","value":"1.3","spread":"0.9"},{"groupId":"BG004","value":"1.3","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 24B:Worthlessness","description":"Measures feelings of worthlessness on a scale of 0 (absent) to 4 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.5","spread":"1.0"},{"groupId":"BG001","value":"1.5","spread":"1.0"},{"groupId":"BG002","value":"1.6","spread":"1.1"},{"groupId":"BG003","value":"1.6","spread":"1.1"},{"groupId":"BG004","value":"1.5","spread":"1.0"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 2:Feelings of Guilt","description":"Measures feelings of guilt on a scale of 0 (absent) to 4 (very guilty).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.8","spread":"0.7"},{"groupId":"BG001","value":"2.0","spread":"0.7"},{"groupId":"BG002","value":"1.8","spread":"0.6"},{"groupId":"BG003","value":"1.7","spread":"0.8"},{"groupId":"BG004","value":"1.8","spread":"0.7"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 3:Suicide","description":"Measures thoughts of suicide on a scale of 0 (absent) to 4 (attempts suicide).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.6","spread":"0.7"},{"groupId":"BG001","value":"0.7","spread":"0.7"},{"groupId":"BG002","value":"0.6","spread":"0.8"},{"groupId":"BG003","value":"0.6","spread":"0.8"},{"groupId":"BG004","value":"0.6","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 4:Insomnia Early","description":"Measures early insomnia on a scale of 0 (no difficulty falling asleep) to 2 (complains of nightly difficulty falling asleep).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.5","spread":"0.8"},{"groupId":"BG001","value":"1.4","spread":"0.8"},{"groupId":"BG002","value":"1.4","spread":"0.8"},{"groupId":"BG003","value":"1.4","spread":"0.8"},{"groupId":"BG004","value":"1.4","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 5:Insomnia Middle","description":"Measures middle insomnia on a scale of 0 (no difficulty) to 2 (waking during the night).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.5","spread":"0.7"},{"groupId":"BG001","value":"1.5","spread":"0.6"},{"groupId":"BG002","value":"1.4","spread":"0.8"},{"groupId":"BG003","value":"1.5","spread":"0.7"},{"groupId":"BG004","value":"1.5","spread":"0.7"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 6:Insomnia Late","description":"Measures late insomnia on a scale of 0 (no difficulty) to 2 (unable to fall asleep again if gets out of bed).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.2","spread":"0.8"},{"groupId":"BG001","value":"1.3","spread":"0.8"},{"groupId":"BG002","value":"1.1","spread":"0.8"},{"groupId":"BG003","value":"1.1","spread":"0.8"},{"groupId":"BG004","value":"1.2","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 7:Work and Activities","description":"Item 7 of the HAMD-24 assesses loss of interest or pleasure in work and activities and is an essential symptom in MDD. Scores range from 0 (no difficulty/no loss) to 4 (difficulty/loss).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2.9","spread":"0.5"},{"groupId":"BG001","value":"2.8","spread":"0.6"},{"groupId":"BG002","value":"2.8","spread":"0.5"},{"groupId":"BG003","value":"2.8","spread":"0.5"},{"groupId":"BG004","value":"2.8","spread":"0.5"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 8:Retardation","description":"Measures slowness of thought and speech; impaired ability to concentrate; decreased motor activity on a scale of 0 (normal speech and thought) to 4 (complete stupor).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.1","spread":"0.7"},{"groupId":"BG001","value":"1.0","spread":"0.7"},{"groupId":"BG002","value":"1.1","spread":"0.8"},{"groupId":"BG003","value":"1.1","spread":"0.9"},{"groupId":"BG004","value":"1.1","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) - Item 9:Agitation","description":"Measures agitation on a scale of 0 (none) to 4 (hand-wringing, nail-biting).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.9","spread":"0.9"},{"groupId":"BG001","value":"0.9","spread":"0.8"},{"groupId":"BG002","value":"0.9","spread":"0.9"},{"groupId":"BG003","value":"1.0","spread":"0.9"},{"groupId":"BG004","value":"0.9","spread":"0.9"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) Anxiety/Somatization Subscale Score","description":"The Anxiety/Somatization subscale (items 10-13, 15, 17) evaluates severity of psychic and somatic manifistations of anxiety as well as agitation. Total subscale scores range from 0 (normal) to 18 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6.8","spread":"2.1"},{"groupId":"BG001","value":"6.9","spread":"1.9"},{"groupId":"BG002","value":"7.1","spread":"2.3"},{"groupId":"BG003","value":"7.3","spread":"2.4"},{"groupId":"BG004","value":"7.0","spread":"2.2"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) Bech Subscale Score","description":"The Bech subscale (Items 1,2,7,8,10,13) evaluates \"core\" symptoms of Major Depressive Disorder (MDD). Total subscale scores range from 0 (normal) to 22 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12.6","spread":"2.0"},{"groupId":"BG001","value":"12.5","spread":"1.7"},{"groupId":"BG002","value":"12.4","spread":"1.9"},{"groupId":"BG003","value":"12.3","spread":"2.2"},{"groupId":"BG004","value":"12.5","spread":"2.0"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) Maier Subscale Score","description":"The Maier subscale (Items 1,2,7,8,9,10) represents the \"core\" symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11.8","spread":"2.2"},{"groupId":"BG001","value":"11.7","spread":"1.9"},{"groupId":"BG002","value":"11.6","spread":"2.2"},{"groupId":"BG003","value":"11.6","spread":"2.4"},{"groupId":"BG004","value":"11.7","spread":"2.2"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) Retardation Subscale Score","description":"The Retardation subscale (Items 1,7,8,14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation. Total subscale scores range from 0 (normal) to 14 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.2","spread":"1.6"},{"groupId":"BG001","value":"8.0","spread":"1.6"},{"groupId":"BG002","value":"8.0","spread":"1.6"},{"groupId":"BG003","value":"7.9","spread":"1.6"},{"groupId":"BG004","value":"8.1","spread":"1.6"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) Sleep Subscale Score","description":"The Sleep subscale (Items 4,5,6) evaluates initial, middle, and late insomnia. Total subscale scores range from 0 (no difficulty) to 6 (difficulty).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.2","spread":"1.6"},{"groupId":"BG001","value":"4.3","spread":"1.5"},{"groupId":"BG002","value":"3.9","spread":"1.7"},{"groupId":"BG003","value":"4.0","spread":"1.5"},{"groupId":"BG004","value":"4.1","spread":"1.6"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale (HAMD-24) Total Score","description":"The 24-item HAMD measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.6","spread":"6.0"},{"groupId":"BG001","value":"28.6","spread":"5.5"},{"groupId":"BG002","value":"28.7","spread":"6.2"},{"groupId":"BG003","value":"29.0","spread":"6.7"},{"groupId":"BG004","value":"28.7","spread":"6.1"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale - Item 12:Somatic Symptoms/Gastrointestinal","description":"Measures gastrointestical somatic symptoms on a scale of 0 (none) to 2 (difficulty eating, requires medication for symptoms).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.7","spread":"0.7"},{"groupId":"BG001","value":"0.6","spread":"0.7"},{"groupId":"BG002","value":"0.6","spread":"0.7"},{"groupId":"BG003","value":"0.7","spread":"0.7"},{"groupId":"BG004","value":"0.7","spread":"0.7"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale - Item 18B:Diurnal Variation-Severity","description":"Measures the severity of the diurnal variation on a scale of 0 (none) to 2 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.8","spread":"0.8"},{"groupId":"BG001","value":"0.9","spread":"0.9"},{"groupId":"BG002","value":"0.9","spread":"0.8"},{"groupId":"BG003","value":"1.0","spread":"0.9"},{"groupId":"BG004","value":"0.9","spread":"0.8"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale - Item 19: Depersonalization and Derealization","description":"Measures feelings of unreality on a scale of 0 (absent) to 4 (incapacitating).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.2","spread":"0.6"},{"groupId":"BG001","value":"0.3","spread":"0.6"},{"groupId":"BG002","value":"0.2","spread":"0.5"},{"groupId":"BG003","value":"0.2","spread":"0.5"},{"groupId":"BG004","value":"0.2","spread":"0.6"}]}]}]},{"title":"Evaluation - 24-Item Hamilton Depression Rating Scale - Item 21:Obsessional and Compulsive Symptoms","description":"Measures obsessional and compulsive symptoms on a scale of 0 (absent) to 2 (severe).","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.1","spread":"0.4"},{"groupId":"BG001","value":"0.1","spread":"0.4"},{"groupId":"BG002","value":"0.1","spread":"0.4"},{"groupId":"BG003","value":"0.1","spread":"0.4"},{"groupId":"BG004","value":"0.1","spread":"0.4"}]}]}]},{"title":"Evaluation - Clinical Global Impressions of Severity Scale (CGI-S) Score","description":"Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.6","spread":"0.6"},{"groupId":"BG001","value":"4.5","spread":"0.6"},{"groupId":"BG002","value":"4.7","spread":"0.7"},{"groupId":"BG003","value":"4.7","spread":"0.7"},{"groupId":"BG004","value":"4.6","spread":"0.7"}]}]}]},{"title":"Evaluation - Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire","description":"A 7-item patitent-rated questionnaire pertaining to a patient's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each of the 7 questions is scored on a 6-point scale ranging fom 1 (greater than normal) to 6 (totally absent). Total score ranges from 7 to 42.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.4","spread":"6.0"},{"groupId":"BG001","value":"26.8","spread":"6.1"},{"groupId":"BG002","value":"28.6","spread":"6.1"},{"groupId":"BG003","value":"28.6","spread":"5.4"},{"groupId":"BG004","value":"28.2","spread":"6.0"}]}]}]},{"title":"Evaluation - Pain Numerical Rating Scale (NRS) Score Item 1","description":"Item 1=Average musculoskeletal pain severity. Participants are asked to rate their average pain over the last week as measured by an 11-point Likert scale. A score of 0 reflects \"no pain\" and a score of 10 reflects \"worst possible pain\".","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.3","spread":"2.8"},{"groupId":"BG001","value":"4.1","spread":"2.7"},{"groupId":"BG002","value":"4.5","spread":"3.1"},{"groupId":"BG003","value":"4.5","spread":"2.8"},{"groupId":"BG004","value":"4.4","spread":"2.9"}]}]}]},{"title":"Evaluation - Pain Numerical Rating Scale (NRS) Score Item 7","description":"Item 7=How much they have been bothered by pain over the last week, as measured by an 11-point Likert scale. A score of 0 reflects \"not bothered at all\" and a score of 10 reflects \"extremely bothered\".","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.7","spread":"3.0"},{"groupId":"BG001","value":"4.5","spread":"3.1"},{"groupId":"BG002","value":"4.7","spread":"3.2"},{"groupId":"BG003","value":"4.9","spread":"3.2"},{"groupId":"BG004","value":"4.7","spread":"3.1"}]}]}]},{"title":"Evaluation - Sheehan Disability Scale (SDS) Item 1","description":"The SDS is completed by the patient and Item 1 is used to assess the effect of the patient's symptoms on their work/school schedule. Scores range from 0 to 10 with higher values indicating greater disruption in the patient's work/school life.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5.5","spread":"2.8"},{"groupId":"BG001","value":"5.4","spread":"2.7"},{"groupId":"BG002","value":"5.6","spread":"2.7"},{"groupId":"BG003","value":"5.3","spread":"2.8"},{"groupId":"BG004","value":"5.5","spread":"2.7"}]}]}]},{"title":"Evaluation - Sheehan Disability Scale (SDS) Item 2","description":"The SDS is completed by the patient and Item 2 is used to assess the effect of the patient's symptoms on their social life/leisure acitivities. Scores range from 0 to 10 with higher values indicating greater disruption in the patient's social life.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6.6","spread":"2.4"},{"groupId":"BG001","value":"6.2","spread":"2.8"},{"groupId":"BG002","value":"6.4","spread":"2.8"},{"groupId":"BG003","value":"5.9","spread":"2.5"},{"groupId":"BG004","value":"6.3","spread":"2.6"}]}]}]},{"title":"Evaluation - Sheehan Disability Scale (SDS) Item 3","description":"The SDS is completed by the patient and Item 3 is used to assess the effect of the patient's symptoms on their family life/home responsibilities. Scores range from 0 to 10 with higher values indicating greater disruption in the patient's family life/home responsibilities.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6.5","spread":"2.5"},{"groupId":"BG001","value":"6.0","spread":"2.6"},{"groupId":"BG002","value":"6.2","spread":"2.6"},{"groupId":"BG003","value":"6.0","spread":"2.5"},{"groupId":"BG004","value":"6.2","spread":"2.6"}]}]}]},{"title":"Evaluation - Sheehan Disability Scale (SDS) Total Score","description":"The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19.0","spread":"6.5"},{"groupId":"BG001","value":"17.8","spread":"7.3"},{"groupId":"BG002","value":"18.4","spread":"7.1"},{"groupId":"BG003","value":"17.5","spread":"7.0"},{"groupId":"BG004","value":"18.3","spread":"6.9"}]}]}]},{"title":"Evaluation - Social Adaptation Self-Evaluation Scale (SASS) Total","description":"A 21-item self-rated scale that evaluates patient social motivation and behavior in depression. Each of the 21 items is scored from 0 (minimal social adjustment) to 3 (maximal social adjustment). Total score ranges from 0 to 60.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.2","spread":"7.3"},{"groupId":"BG001","value":"29.1","spread":"8.4"},{"groupId":"BG002","value":"27.6","spread":"8.2"},{"groupId":"BG003","value":"29.3","spread":"8.2"},{"groupId":"BG004","value":"28.0","spread":"8.0"}]}]}]},{"title":"History - Age at First Episode","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30.0","spread":"13.2"},{"groupId":"BG001","value":"31.2","spread":"13.7"},{"groupId":"BG002","value":"30.7","spread":"13.6"},{"groupId":"BG003","value":"30.0","spread":"12.6"},{"groupId":"BG004","value":"30.4","spread":"13.3"}]}]}]},{"title":"History - How Long was Last Major Depressive Disorder (MDD) Episode","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.7","spread":"6.3"},{"groupId":"BG001","value":"5.0","spread":"7.4"},{"groupId":"BG002","value":"5.2","spread":"6.9"},{"groupId":"BG003","value":"6.5","spread":"14.5"},{"groupId":"BG004","value":"5.2","spread":"8.6"}]}]}]},{"title":"History - Interval Between Start of Current and Remission of Last MDD Episode","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13.2","spread":"20.1"},{"groupId":"BG001","value":"12.5","spread":"24.3"},{"groupId":"BG002","value":"13.1","spread":"22.1"},{"groupId":"BG003","value":"13.1","spread":"22.2"},{"groupId":"BG004","value":"13.0","spread":"21.8"}]}]}]},{"title":"History - Number of Previous Episodes","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"number of previous episodes","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.0","spread":"4.8"},{"groupId":"BG001","value":"3.8","spread":"4.3"},{"groupId":"BG002","value":"4.9","spread":"5.4"},{"groupId":"BG003","value":"5.2","spread":"5.4"},{"groupId":"BG004","value":"4.5","spread":"5.1"}]}]}]},{"title":"History - Time Since First Episode Date","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12.3","spread":"11.6"},{"groupId":"BG001","value":"12.5","spread":"11.6"},{"groupId":"BG002","value":"14.0","spread":"11.5"},{"groupId":"BG003","value":"14.0","spread":"12.0"},{"groupId":"BG004","value":"13.2","spread":"11.7"}]}]}]},{"title":"History - Time Since Most Recent Episode","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44.0","spread":"60.2"},{"groupId":"BG001","value":"48.8","spread":"69.5"},{"groupId":"BG002","value":"51.4","spread":"103.3"},{"groupId":"BG003","value":"59.2","spread":"111.2"},{"groupId":"BG004","value":"49.8","spread":"87.3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to 8 Weeks in 24-Item Hamilton Depression Rating Scale (HAMD-24) Item 7 (Work and Activities)","description":"Item 7 of the HAMD-24 assesses loss of interest or pleasure in work and activities and is an essential symptom in MDD. Scores range from 0 (no difficulty/no loss) to 4 (difficulty/loss).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"baseline, 8 weeks","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"110"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"0.07"},{"groupId":"OG001","value":"-1.07","spread":"0.11"},{"groupId":"OG002","value":"-1.37","spread":"0.07"},{"groupId":"OG003","value":"-0.93","spread":"0.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.051","pValueComment":"Repeated Measures Analysis for Group A change from baseline to 8 week endpoint.","statisticalMethod":"Mixed Models Analysis","statisticalComment":"Model=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Repeated Measures Analysis for Group B change from baseline to 8 week endpoint.","statisticalMethod":"Mixed Models Analysis","statisticalComment":"Model=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in the 17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score and HAMD-24 Subscales (8 Week Endpoint for Maier Subscale)","description":"The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe). Please see baseline demographics for subscale total scores.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 8 weeks, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"110"}]}],"classes":[{"title":"Total Score 12 Week Change (n=194,n=59,n=195,n=64)","categories":[{"measurements":[{"groupId":"OG000","value":"-12.64","spread":"0.50"},{"groupId":"OG001","value":"-10.33","spread":"0.79"},{"groupId":"OG002","value":"-12.11","spread":"0.47"},{"groupId":"OG003","value":"-8.48","spread":"0.75"}]}]},{"title":"Maier 8 Week Change (n=214,n=102,n=220,n=110)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.11","spread":"0.27"},{"groupId":"OG001","value":"-4.69","spread":"0.38"},{"groupId":"OG002","value":"-6.13","spread":"0.24"},{"groupId":"OG003","value":"-4.45","spread":"0.33"}]}]},{"title":"Anxiety 12 Week Change (n=194,n=59,n=195,n=64)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.52","spread":"0.16"},{"groupId":"OG001","value":"-3.12","spread":"0.27"},{"groupId":"OG002","value":"-3.52","spread":"0.17"},{"groupId":"OG003","value":"-2.44","spread":"0.27"}]}]},{"title":"Bech 12 Week Change (n=194,n=59,n=195,n=64)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.38","spread":"0.29"},{"groupId":"OG001","value":"-6.17","spread":"0.47"},{"groupId":"OG002","value":"-6.98","spread":"0.27"},{"groupId":"OG003","value":"-4.70","spread":"0.43"}]}]},{"title":"Retardation 12 Week Change (n=194,n=59,n=195,n=64)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.72","spread":"0.19"},{"groupId":"OG001","value":"-4.06","spread":"0.32"},{"groupId":"OG002","value":"-4.49","spread":"0.19"},{"groupId":"OG003","value":"-3.05","spread":"0.31"}]}]},{"title":"Sleep 12 Week Change (n=194,n=59,n=195,n=64)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"0.13"},{"groupId":"OG001","value":"-1.72","spread":"0.22"},{"groupId":"OG002","value":"-1.91","spread":"0.12"},{"groupId":"OG003","value":"-1.48","spread":"0.20"}]}]},{"title":"Total Score 9 Month Change (n=29,n=9,n=33,n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-14.38","spread":"1.02"},{"groupId":"OG001","value":"-13.38","spread":"1.86"},{"groupId":"OG002","value":"-9.56","spread":"1.26"},{"groupId":"OG003","value":"-5.92","spread":"2.32"}]}]},{"title":"Anxiety 9 Month Change (n=29,n=9,n=33,n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.09","spread":"0.30"},{"groupId":"OG001","value":"-3.88","spread":"0.56"},{"groupId":"OG002","value":"-3.44","spread":"0.35"},{"groupId":"OG003","value":"-2.77","spread":"0.65"}]}]},{"title":"Bech 9 Month Change (n=29,n=9,n=33,n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.56","spread":"0.58"},{"groupId":"OG001","value":"-8.02","spread":"1.04"},{"groupId":"OG002","value":"-5.80","spread":"0.70"},{"groupId":"OG003","value":"-4.35","spread":"1.30"}]}]},{"title":"Retardation 9 Month Change (n=29,n=9,n=33,n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.35","spread":"0.40"},{"groupId":"OG001","value":"-5.83","spread":"0.72"},{"groupId":"OG002","value":"-3.68","spread":"0.44"},{"groupId":"OG003","value":"-2.52","spread":"0.81"}]}]},{"title":"Sleep 9 Month Change (n=29,n=9,n=33,n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.77","spread":"0.23"},{"groupId":"OG001","value":"-2.56","spread":"0.40"},{"groupId":"OG002","value":"-2.55","spread":"0.26"},{"groupId":"OG003","value":"-1.95","spread":"0.48"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.013","pValueComment":"P-value for Total Score 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for Total Score 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.026","pValueComment":"P-value for Maier 8 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for Maier 8 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.202","pValueComment":"P-value for Anxiety/Somatization 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for Anxiety/Somatization 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.027","pValueComment":"P-value for Bech 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for Bech 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.076","pValueComment":"P-value for Retardation 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for Retardation 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.149","pValueComment":"P-value for Sleep 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.062","pValueComment":"P-value for Sleep 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.629","pValueComment":"P-value for Total Score 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.194","pValueComment":"P-value for Total Score 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.525","pValueComment":"P-value for Maier 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.595","pValueComment":"P-value for Maier 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.736","pValueComment":"P-value for Anxiety/Somatization 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.368","pValueComment":"P-value for Anxiety/Somatization 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.660","pValueComment":"P-value for Bech 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.334","pValueComment":"P-value for Bech 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.568","pValueComment":"P-value for Retardation 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.216","pValueComment":"P-value for Retardation 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.646","pValueComment":"P-value for Sleep 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.275","pValueComment":"P-value for Sleep 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Total Score","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"194"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-16.24","spread":"0.62"},{"groupId":"OG001","value":"-13.24","spread":"1.01"},{"groupId":"OG002","value":"-15.60","spread":"0.61"},{"groupId":"OG003","value":"-10.94","spread":"0.96"}]}]},{"title":"9 Month Change (n=29, n=8, n=32, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-17.05","spread":"1.15"},{"groupId":"OG001","value":"-15.22","spread":"2.14"},{"groupId":"OG002","value":"-13.49","spread":"1.45"},{"groupId":"OG003","value":"-9.12","spread":"2.64"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.011","pValueComment":"P-value for 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value for 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline)","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.449","pValueComment":"P-value for 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.167","pValueComment":"P-value for 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in the HAMD-24 Item 1:Depressed Mood","description":"Measures depressed mood on a scale of 0 (absent) to 4 (very depressed).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.86","spread":"0.07"},{"groupId":"OG001","value":"-1.52","spread":"0.12"},{"groupId":"OG002","value":"-1.78","spread":"0.07"},{"groupId":"OG003","value":"-1.15","spread":"0.12"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"0.20"},{"groupId":"OG001","value":"-1.26","spread":"0.34"},{"groupId":"OG002","value":"-1.98","spread":"0.19"},{"groupId":"OG003","value":"-1.65","spread":"0.35"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.016","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.653","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.417","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 2:Feelings of Guilt","description":"Measures feelings of guilt on a scale of 0 (absent) to 4 (very guilty).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.19","spread":"0.06"},{"groupId":"OG001","value":"-1.06","spread":"0.09"},{"groupId":"OG002","value":"-1.15","spread":"0.05"},{"groupId":"OG003","value":"-0.89","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"0.10"},{"groupId":"OG001","value":"-1.21","spread":"0.17"},{"groupId":"OG002","value":"-1.37","spread":"0.06"},{"groupId":"OG003","value":"-1.16","spread":"0.13"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.204","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change(Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.011","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.571","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.133","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 3:Suicide","description":"Measures thoughts of suicide on a scale of 0 (absent) to 4 (attempts suicide).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 Months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"0.04"},{"groupId":"OG001","value":"-0.30","spread":"0.06"},{"groupId":"OG002","value":"-0.40","spread":"0.04"},{"groupId":"OG003","value":"-0.29","spread":"0.06"}]}]},{"title":"9 Month Change (n=29, n= 9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"0.10"},{"groupId":"OG001","value":"-1.21","spread":"0.17"},{"groupId":"OG002","value":"-1.37","spread":"0.06"},{"groupId":"OG003","value":"-1.16","spread":"0.13"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.023","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.100","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.571","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.133","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 4:Insomnia Early","description":"Measures early insomnia on a scale of 0 (no difficulty falling asleep) to 2 (complains of nightly difficulty falling asleep).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.06"},{"groupId":"OG001","value":"-0.61","spread":"0.10"},{"groupId":"OG002","value":"-0.68","spread":"0.06"},{"groupId":"OG003","value":"-0.46","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.85","spread":"0.13"},{"groupId":"OG001","value":"-0.77","spread":"0.23"},{"groupId":"OG002","value":"-0.71","spread":"0.13"},{"groupId":"OG003","value":"-0.86","spread":"0.24"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.332","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.041","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.775","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.588","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 5:Insomnia Middle","description":"Measures middle insomnia on a scale of 0 (no difficulty) to 2 (waking during the night).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":"0.05"},{"groupId":"OG001","value":"-0.74","spread":"0.09"},{"groupId":"OG002","value":"-0.66","spread":"0.06"},{"groupId":"OG003","value":"-0.59","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.99","spread":"0.11"},{"groupId":"OG001","value":"-0.92","spread":"0.19"},{"groupId":"OG002","value":"-0.99","spread":"0.09"},{"groupId":"OG003","value":"-0.67","spread":"0.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.624","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.473","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.787","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.086","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 6:Insomnia Late","description":"Measures late insomnia on a scale of 0 (no difficulty) to 2 (unable to fall asleep again if gets out of bed).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"0.05"},{"groupId":"OG001","value":"-0.49","spread":"0.09"},{"groupId":"OG002","value":"-0.57","spread":"0.05"},{"groupId":"OG003","value":"-0.45","spread":"0.08"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.94","spread":"0.05"},{"groupId":"OG001","value":"-0.87","spread":"0.08"},{"groupId":"OG002","value":"-0.78","spread":"0.10"},{"groupId":"OG003","value":"-0.52","spread":"0.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.099","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.223","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.473","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.233","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 9 Month Endpoint in HAMD-24 - Item 7:Work and Activities","description":"Item 7 of the HAMD-24 assesses loss of interest or pleasure in work and activities and is an essential symptom in MDD. Scores range from 0 (no difficulty/no loss) to 4 (difficulty/loss).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.43","spread":"0.10"},{"groupId":"OG001","value":"-2.55","spread":"0.19"},{"groupId":"OG002","value":"-1.66","spread":"0.13"},{"groupId":"OG003","value":"-1.50","spread":"0.25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.577","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.567","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 8:Retardation","description":"Measures slowness of thought and speech; impaired ability to concentrate; decreased motor activity on a scale of 0 (normal speech and thought) to 4 (complete stupor).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.04"},{"groupId":"OG001","value":"-0.69","spread":"0.07"},{"groupId":"OG002","value":"-0.66","spread":"0.04"},{"groupId":"OG003","value":"-0.51","spread":"0.07"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.89","spread":"0.05"},{"groupId":"OG001","value":"-0.90","spread":"0.09"},{"groupId":"OG002","value":"-1.66","spread":"0.13"},{"groupId":"OG003","value":"-1.50","spread":"0.25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.670","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.059","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.930","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.567","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 9:Agitation","description":"Measures agitation on a scale of 0 (none) to 4 (hand-wringing, nail-biting)","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.04"},{"groupId":"OG001","value":"-0.48","spread":"0.07"},{"groupId":"OG002","value":"-0.44","spread":"0.05"},{"groupId":"OG003","value":"-0.41","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.07"},{"groupId":"OG001","value":"-0.61","spread":"0.12"},{"groupId":"OG002","value":"-0.57","spread":"0.11"},{"groupId":"OG003","value":"-0.78","spread":"0.21"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.896","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.796","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.571","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.381","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 10:Anxiety (Psychic)","description":"Measures anxiety on a scale of 0 (no difficulty) to 4 (fears expressed)","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"0.06"},{"groupId":"OG001","value":"-0.90","spread":"0.10"},{"groupId":"OG002","value":"-1.15","spread":"0.06"},{"groupId":"OG003","value":"-0.81","spread":"0.10"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"0.12"},{"groupId":"OG001","value":"-1.13","spread":"0.20"},{"groupId":"OG002","value":"-1.41","spread":"0.12"},{"groupId":"OG003","value":"-1.70","spread":"0.22"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.038","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.665","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.253","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 11:Anxiety (Somatic)","description":"Measures physiological concomitants of anxiety on a scale of 0 (absent) to 4 (incapacitating).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"0.05"},{"groupId":"OG001","value":"-0.65","spread":"0.09"},{"groupId":"OG002","value":"-0.68","spread":"0.06"},{"groupId":"OG003","value":"-0.57","spread":"0.10"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"0.11"},{"groupId":"OG001","value":"-0.94","spread":"0.19"},{"groupId":"OG002","value":"-1.20","spread":"0.08"},{"groupId":"OG003","value":"-1.18","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.723","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.312","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.853","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.913","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 12:Somatic Symptoms/Gastrointestinal","description":"Measures gastrointestical somatic symptoms on a scale of 0 (none) to 2 (difficulty eating, requires medication for symptoms).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"0.03"},{"groupId":"OG001","value":"-0.52","spread":"0.06"},{"groupId":"OG002","value":"-0.40","spread":"0.03"},{"groupId":"OG003","value":"-0.32","spread":"0.05"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"0.11"},{"groupId":"OG001","value":"-0.94","spread":"0.19"},{"groupId":"OG002","value":"-0.46","spread":"0.05"},{"groupId":"OG003","value":"-0.47","spread":"0.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.234","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.216","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.853","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.908","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 13:Somatic Symptoms/General","description":"Measures general somatic symptoms on a scale of 0 (none) to 2 (any clear-cut symptoms).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"0.05"},{"groupId":"OG001","value":"-0.88","spread":"0.09"},{"groupId":"OG002","value":"-0.75","spread":"0.05"},{"groupId":"OG003","value":"-0.49","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":"0.11"},{"groupId":"OG001","value":"-1.18","spread":"0.20"},{"groupId":"OG002","value":"-0.94","spread":"0.13"},{"groupId":"OG003","value":"-0.83","spread":"0.25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.789","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.012","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.414","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.717","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 14:Genital Symptoms","description":"Measures genital symptoms (loss of libido, menstrual disturbances) on a scale of 0 (absent) to 2 (severe).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"0.05"},{"groupId":"OG001","value":"-0.54","spread":"0.09"},{"groupId":"OG002","value":"-0.55","spread":"0.06"},{"groupId":"OG003","value":"-0.40","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.89","spread":"0.13"},{"groupId":"OG001","value":"-0.77","spread":"0.22"},{"groupId":"OG002","value":"-0.68","spread":"0.08"},{"groupId":"OG003","value":"-0.30","spread":"0.15"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.780","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.152","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.637","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.024","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 15:Hypochondriasis","description":"Measures hypochondriasis on a scale of 0 (not present) to 4 (hypochondriacal delusions).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"0.04"},{"groupId":"OG001","value":"-0.41","spread":"0.06"},{"groupId":"OG002","value":"-0.52","spread":"0.05"},{"groupId":"OG003","value":"-0.41","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"82.99"},{"groupId":"OG001","value":"-0.53","spread":"144.40"},{"groupId":"OG002","value":"-0.61","spread":"0.09"},{"groupId":"OG003","value":"-0.41","spread":"0.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.517","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.256","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.268","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 16:Loss of Weight","description":"Measures weight loss since last visit on a scale of 0 (no weight loss) to 2 (definite weight loss caused by present illness).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.02"},{"groupId":"OG001","value":"-0.20","spread":"0.04"},{"groupId":"OG002","value":"-0.25","spread":"0.02"},{"groupId":"OG003","value":"-0.24","spread":"0.04"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"82.99"},{"groupId":"OG001","value":"-0.53","spread":"144.40"},{"groupId":"OG002","value":"-0.61","spread":"0.09"},{"groupId":"OG003","value":"-0.41","spread":"0.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.741","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.722","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.268","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 17:Insight","description":"Measures insight on a scale of 0 (acknowledges being depressed and ill) to 2 (denies being ill at all).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.01"},{"groupId":"OG001","value":"-0.07","spread":"0.02"},{"groupId":"OG002","value":"-0.01","spread":"0.01"},{"groupId":"OG003","value":"-0.01","spread":"0.02"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"82.99"},{"groupId":"OG001","value":"-0.53","spread":"144.40"},{"groupId":"OG002","value":"-0.61","spread":"0.09"},{"groupId":"OG003","value":"-0.41","spread":"0.16"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.723","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.949","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.268","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18A:Diurnal Variation","description":"Measures whether symptoms are worse in morning or evening on a scale of 0 (no variation), 1 (worse in morning), or 2 (worse in evening).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"0.05"},{"groupId":"OG001","value":"-0.36","spread":"0.09"},{"groupId":"OG002","value":"-0.45","spread":"0.05"},{"groupId":"OG003","value":"-0.13","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"0.12"},{"groupId":"OG001","value":"-0.26","spread":"0.20"},{"groupId":"OG002","value":"-0.77","spread":"0.13"},{"groupId":"OG003","value":"-0.70","spread":"0.25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.682","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.200","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.813","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 18B:Diurnal Variation-Severity","description":"Measures the severity of the diurnal variation on a scale of 0 (none) to 2 (severe).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.04"},{"groupId":"OG001","value":"-0.49","spread":"0.07"},{"groupId":"OG002","value":"-0.42","spread":"0.05"},{"groupId":"OG003","value":"-0.21","spread":"0.08"}]}]},{"title":"9 Month Change (n=29, n=8, n=32, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.07"},{"groupId":"OG001","value":"-0.54","spread":"0.12"},{"groupId":"OG002","value":"-0.63","spread":"0.08"},{"groupId":"OG003","value":"-0.56","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.438","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.018","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.692","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.668","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 19: Depersonalization and Derealization","description":"Measures feelings of unreality on a scale of 0 (absent) to 4 (incapacitating).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.02"},{"groupId":"OG001","value":"-0.21","spread":"0.03"},{"groupId":"OG002","value":"-0.15","spread":"0.02"},{"groupId":"OG003","value":"-0.14","spread":"0.03"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.07"},{"groupId":"OG001","value":"-0.54","spread":"0.12"},{"groupId":"OG002","value":"-0.63","spread":"0.08"},{"groupId":"OG003","value":"-0.56","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.588","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.758","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.692","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.668","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 20:Paranoid Symptoms","description":"Measures paranoid symptoms on a scale of 0 (none) to 2 (severe).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.02"},{"groupId":"OG001","value":"-0.12","spread":"0.04"},{"groupId":"OG002","value":"-0.13","spread":"0.02"},{"groupId":"OG003","value":"-0.11","spread":"0.03"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.07"},{"groupId":"OG001","value":"-0.54","spread":"0.12"},{"groupId":"OG002","value":"-0.63","spread":"0.08"},{"groupId":"OG003","value":"-0.56","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.507","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.466","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.692","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.668","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 21:Obsessional and Compulsive Symptoms","description":"Measures obsessional and compulsive symptoms on a scale of 0 (absent) to 2 (severe).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.02"},{"groupId":"OG001","value":"-0.06","spread":"0.03"},{"groupId":"OG002","value":"-0.04","spread":"0.02"},{"groupId":"OG003","value":"-0.06","spread":"0.03"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.07"},{"groupId":"OG001","value":"-0.54","spread":"0.12"},{"groupId":"OG002","value":"-0.63","spread":"0.08"},{"groupId":"OG003","value":"-0.56","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.487","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.678","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.692","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.668","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 22B:Helplessness","description":"Measures feelings of helplessness on a scale of 0 (absent) to 4 (severe).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"0.05"},{"groupId":"OG001","value":"-0.88","spread":"0.09"},{"groupId":"OG002","value":"-0.98","spread":"0.06"},{"groupId":"OG003","value":"-0.81","spread":"0.10"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":"0.09"},{"groupId":"OG001","value":"-0.90","spread":"0.16"},{"groupId":"OG002","value":"-1.34","spread":"9.63"},{"groupId":"OG003","value":"-1.24","spread":"17.77"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.505","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.135","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.175","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 23B:Hopelessness","description":"Measures feelings of hopelessness on a scale of 0 (absent) to 4 (expresses feelings of discouragement, despair, and/or pessimism about the future which cannot be dispelled).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":"0.05"},{"groupId":"OG001","value":"-0.74","spread":"0.08"},{"groupId":"OG002","value":"-0.80","spread":"0.05"},{"groupId":"OG003","value":"-0.51","spread":"0.08"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"0.08"},{"groupId":"OG001","value":"-1.34","spread":"0.15"},{"groupId":"OG002","value":"-0.92","spread":"0.07"},{"groupId":"OG003","value":"-0.85","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.175","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.576","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.676","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in HAMD-24 - Item 24B:Worthlessness","description":"Measures feelings of worthlessness on a scale of 0 (absent) to 4 (severe).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.00","spread":"0.06"},{"groupId":"OG001","value":"-0.95","spread":"0.09"},{"groupId":"OG002","value":"-0.95","spread":"0.06"},{"groupId":"OG003","value":"-0.79","spread":"0.09"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"0.08"},{"groupId":"OG001","value":"-1.34","spread":"0.15"},{"groupId":"OG002","value":"-0.92","spread":"0.07"},{"groupId":"OG003","value":"-0.85","spread":"0.14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.675","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.139","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.576","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.676","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment).","description":"The 30-item BPOMS measures mood states and has 6 factors: tension-anxiety, depression-dejection, anxiety-hostility, fatigue, confusion, and vigor. Item scores: 0 (not at all) to 4 (extremely). Each factor scores range from 0 to 20. The Total score is sum of all factor scores minus the factor score for vigor (Total=Ten+Dep+Ang+Fat+Con-Vig).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"193"},{"groupId":"OG003","value":"63"}]}],"classes":[{"title":"Total Score (n=192,n=54,n=185,n=61)","categories":[{"measurements":[{"groupId":"OG000","value":"-26.41","spread":"1.44"},{"groupId":"OG001","value":"-18.88","spread":"2.38"},{"groupId":"OG002","value":"-28.67","spread":"1.52"},{"groupId":"OG003","value":"-22.67","spread":"2.37"}]}]},{"title":"Tension-Anxiety (n=193,n=58,n=193,n=62)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.37","spread":"0.26"},{"groupId":"OG001","value":"-3.20","spread":"0.44"},{"groupId":"OG002","value":"-4.61","spread":"0.30"},{"groupId":"OG003","value":"-4.05","spread":"0.49"}]}]},{"title":"Depression-Dejection (n=193,n=58,n=191,n=62)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.30","spread":"0.33"},{"groupId":"OG001","value":"-4.64","spread":"0.55"},{"groupId":"OG002","value":"-6.78","spread":"0.34"},{"groupId":"OG003","value":"-5.03","spread":"0.53"}]}]},{"title":"Anger-Hostility (n=193,n=58,n=192,n=63)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.46","spread":"0.28"},{"groupId":"OG001","value":"-3.09","spread":"0.46"},{"groupId":"OG002","value":"-4.94","spread":"0.30"},{"groupId":"OG003","value":"-3.63","spread":"0.48"}]}]},{"title":"Vigor-Activity (n=192,n=55,192,n=63)","categories":[{"measurements":[{"groupId":"OG000","value":"2.55","spread":"0.29"},{"groupId":"OG001","value":"1.82","spread":"0.49"},{"groupId":"OG002","value":"2.57","spread":"0.32"},{"groupId":"OG003","value":"1.48","spread":"0.51"}]}]},{"title":"Fatigue-Inertia (n=193,n=57,n=190,n=63)","categories":[{"measurements":[{"groupId":"OG000","value":"-5.30","spread":"0.36"},{"groupId":"OG001","value":"-4.68","spread":"0.59"},{"groupId":"OG002","value":"-6.08","spread":"0.37"},{"groupId":"OG003","value":"-5.54","spread":"0.59"}]}]},{"title":"Confusion-Bewilderment (n=192,n=58,n=189,n=62)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.62","spread":"0.23"},{"groupId":"OG001","value":"-2.86","spread":"0.39"},{"groupId":"OG002","value":"-3.56","spread":"0.25"},{"groupId":"OG003","value":"-3.10","spread":"0.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.031","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.020","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Tension-Anxiety (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.324","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Tension-Anxiety (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.010","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Depression-Dejection (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.005","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Depression-Dejection (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.010","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Anger-Hostility (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.019","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Anger-Hostility (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.201","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Vigor-Activity (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.069","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Vigor-Activity (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.368","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Fatigue-Inertia (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.435","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Fatigue-Inertia (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.090","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Confusion-Bewilderment (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.313","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Confusion-Bewilderment (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 9 Month Endpoint in 30-Item Brief Profile of Mood States (BPOMS) Scale and Subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment)","description":"The 30-item BPOMS measures mood states and has 6 factors: tension-anxiety, depression-dejection, anxiety-hostility, fatigue, confusion, and vigor. Item scores: 0 (not at all) to 4 (extremely). Each factor scores range from 0 to 20. The Total score is sum of all factor scores minus the factor score for vigor (Total=Ten+Dep+Ang+Fat+Con-Vig).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"9"}]}],"classes":[{"title":"Total Score","categories":[{"measurements":[{"groupId":"OG000","value":"-25.67","spread":"2.83"},{"groupId":"OG001","value":"-22.99","spread":"4.89"},{"groupId":"OG002","value":"-28.39","spread":"2.46"},{"groupId":"OG003","value":"-25.51","spread":"4.68"}]}]},{"title":"Tension-Anxiety","categories":[{"measurements":[{"groupId":"OG000","value":"-5.36","spread":"0.51"},{"groupId":"OG001","value":"-4.18","spread":"0.88"},{"groupId":"OG002","value":"-4.68","spread":"0.50"},{"groupId":"OG003","value":"-3.50","spread":"0.94"}]}]},{"title":"Depression-Dejection","categories":[{"measurements":[{"groupId":"OG000","value":"-7.60","spread":"0.60"},{"groupId":"OG001","value":"-6.49","spread":"1.04"},{"groupId":"OG002","value":"-7.18","spread":"0.63"},{"groupId":"OG003","value":"-5.56","spread":"1.24"}]}]},{"title":"Anger-Hostility","categories":[{"measurements":[{"groupId":"OG000","value":"-4.34","spread":"0.60"},{"groupId":"OG001","value":"-3.38","spread":"1.04"},{"groupId":"OG002","value":"-5.98","spread":"0.40"},{"groupId":"OG003","value":"-4.99","spread":"0.73"}]}]},{"title":"Vigor-Activity","categories":[{"measurements":[{"groupId":"OG000","value":"2.63","spread":"0.78"},{"groupId":"OG001","value":"3.11","spread":"1.39"},{"groupId":"OG002","value":"2.00","spread":"0.74"},{"groupId":"OG003","value":"3.04","spread":"1.42"}]}]},{"title":"Fatigue-Inertia","categories":[{"measurements":[{"groupId":"OG000","value":"-7.43","spread":"0.73"},{"groupId":"OG001","value":"-7.40","spread":"1.26"},{"groupId":"OG002","value":"-6.34","spread":"0.59"},{"groupId":"OG003","value":"-7.03","spread":"1.17"}]}]},{"title":"Confusion-Bewilderment","categories":[{"measurements":[{"groupId":"OG000","value":"-3.95","spread":"0.45"},{"groupId":"OG001","value":"-2.47","spread":"0.79"},{"groupId":"OG002","value":"-3.54","spread":"0.35"},{"groupId":"OG003","value":"-3.07","spread":"0.64"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.639","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.584","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.251","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Tension-Anxiety (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.265","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Tension-Anxiety (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.366","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Depression-Dejection (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.257","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Depression-Dejection (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.426","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Anger-Hostility (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.234","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Anger-Hostility (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.765","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Vigor-Activity (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.522","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Vigor-Activity (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.986","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Fatigue-Inertia (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.602","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Fatigue-Inertia (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.110","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Confusion-Bewilderment (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.505","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Confusion-Bewilderment(Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores","description":"The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Individual item scores range from 0 to 10. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"Work Life (n=133,n=43,n=140,n=49)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.47","spread":"0.22"},{"groupId":"OG001","value":"-2.12","spread":"0.34"},{"groupId":"OG002","value":"-1.98","spread":"0.22"},{"groupId":"OG003","value":"-1.22","spread":"0.36"}]}]},{"title":"Social Life (n=194,n=59,n=195,n=63)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.93","spread":"0.19"},{"groupId":"OG001","value":"-2.50","spread":"0.31"},{"groupId":"OG002","value":"-2.67","spread":"0.19"},{"groupId":"OG003","value":"-1.97","spread":"0.30"}]}]},{"title":"Family Life (n=194,n=59,n=195,n=63)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.81","spread":"0.19"},{"groupId":"OG001","value":"-2.19","spread":"0.32"},{"groupId":"OG002","value":"-2.66","spread":"0.19"},{"groupId":"OG003","value":"-1.56","spread":"0.31"}]}]},{"title":"Total Score (n=195,n=59,n=195,n=63)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.32","spread":"0.53"},{"groupId":"OG001","value":"-6.84","spread":"0.87"},{"groupId":"OG002","value":"-7.70","spread":"0.52"},{"groupId":"OG003","value":"-4.94","spread":"0.84"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.366","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Work Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.065","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Work Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.229","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Social Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.044","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Social Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.092","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Family Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Family Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.142","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score(Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.005","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 9 Month Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscores","description":"The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Individual item scores range from 0 to 10. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"10"}]}],"classes":[{"title":"Work Life (n=22, n=8, n=22, n=7)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.88","spread":"0.69"},{"groupId":"OG001","value":"-4.01","spread":"1.10"},{"groupId":"OG002","value":"-2.26","spread":"0.37"},{"groupId":"OG003","value":"-2.16","spread":"0.66"}]}]},{"title":"Social Life (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.15","spread":"0.37"},{"groupId":"OG001","value":"-4.35","spread":"0.65"},{"groupId":"OG002","value":"-3.88","spread":"0.33"},{"groupId":"OG003","value":"-3.66","spread":"0.62"}]}]},{"title":"Family Life (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.46","spread":"0.36"},{"groupId":"OG001","value":"-2.99","spread":"0.64"},{"groupId":"OG002","value":"-3.30","spread":"0.34"},{"groupId":"OG003","value":"-3.07","spread":"0.66"}]}]},{"title":"Total Score (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-11.60","spread":"1.02"},{"groupId":"OG001","value":"-11.15","spread":"1.79"},{"groupId":"OG002","value":"-9.42","spread":"0.97"},{"groupId":"OG003","value":"-8.67","spread":"1.88"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.921","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Work Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.895","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Work Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.789","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Social Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.761","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Social Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.519","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Family Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.755","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Family Life (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.829","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.723","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Total Score (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7","description":"Relative contribution of improvement on the mood states, defined by BPOMS total score (calculated from subscales) to overall improvement in work and activities, HAMD-24 item 7 using path analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"coefficient","timeFrame":"Over 12 weeks","groups":[{"id":"OG000","title":"Group A - Ordinary Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression in the Duloxetine 60 mg group."},{"id":"OG001","title":"Group A - Standardized Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression expressed in units of standard deviation in the Duloxetine 60 mg group."},{"id":"OG002","title":"Group B - Ordinary Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression in the Duloxetine 60 mg group."},{"id":"OG003","title":"Group B - Standardized Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression expressed in units of standard deviation in the Duloxetine 60 mg group."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"110"}]}],"classes":[{"title":"Direct Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"-0.032"},{"groupId":"OG001","value":"-0.012"},{"groupId":"OG002","value":"0.219"},{"groupId":"OG003","value":"0.087"}]}]},{"title":"Indirect Treatment Effect from BPOMS Total Score","categories":[{"measurements":[{"groupId":"OG000","value":"0.376"},{"groupId":"OG001","value":"0.145"},{"groupId":"OG002","value":"0.209"},{"groupId":"OG003","value":"0.083"}]}]},{"title":"Total Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"0.343"},{"groupId":"OG001","value":"0.132"},{"groupId":"OG002","value":"0.428"},{"groupId":"OG003","value":"0.170"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.753","pValueComment":"P-value for Direct Treatment Effect","statisticalMethod":"Regression, Linear","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.036","pValueComment":"P-value for Direct Treatment Effect","statisticalMethod":"Regression, Linear","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Path Analysis of BPOMS Total Score to Overall Improvement in HAMD-24 Item 7 - Percent of Total Effect","description":"For Group A, at least one effect was in the opposite direction, percent of total effect was not calculated.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of total effect","timeFrame":"over 12 weeks","groups":[{"id":"OG000","title":"Group B - Percent of Total Effect","description":"The percentage of the total treatment effect explained by the direct and indirect effects of treatment in the duloxetine 60 mg group."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"}]}],"classes":[{"title":"Direct Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"51.14"}]}]},{"title":"Indirect Treatment Effect from BPOMS Total Score","categories":[{"measurements":[{"groupId":"OG000","value":"48.86"}]}]},{"title":"Total Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"100.00"}]}]}]},{"type":"SECONDARY","title":"Path Analysis of BPOMS Total Score to Overall Improvement in Sheehan Disability Scale (SDS) Total Score","description":"Relative contribution of improvement on the mood states, defined by BPOMS total score (determined from subscales) to overall improvement in SDS total score using path analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"coefficient","timeFrame":"over 12 weeks","groups":[{"id":"OG000","title":"Group A - Ordinary Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression in the Duloxetine 60 mg group."},{"id":"OG001","title":"Group A - Standardized Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression expressed in units of standard deviation in the Duloxetine 60 mg group."},{"id":"OG002","title":"Group B - Ordinary Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression in the Duloxetine 60 mg group."},{"id":"OG003","title":"Group B - Standardized Coefficient","description":"Mathematical estimate of the relationship between the dependent variable and the independent variable from linear regression expressed in units of standard deviation in the Duloxetine 60 mg group."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"110"}]}],"classes":[{"title":"Direct Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"-0.577"},{"groupId":"OG001","value":"-0.032"},{"groupId":"OG002","value":"0.955"},{"groupId":"OG003","value":"0.052"}]}]},{"title":"Indirect Treatment Effect from BPOMS Total Score","categories":[{"measurements":[{"groupId":"OG000","value":"2.754"},{"groupId":"OG001","value":"0.151"},{"groupId":"OG002","value":"1.761"},{"groupId":"OG003","value":"0.095"}]}]},{"title":"Total Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"2.177"},{"groupId":"OG001","value":"0.120"},{"groupId":"OG002","value":"2.716"},{"groupId":"OG003","value":"0.147"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.342","pValueComment":"P-value for Direct Treatment Effect","statisticalMethod":"Regression, Linear","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.111","pValueComment":"P-value for Direct Treatment Effect","statisticalMethod":"Regression, Linear","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Path Analysis of BPOMS Total Score to Overall Improvement in SDS Total Score - Percent of Total Effect","description":"For Group A, at least one effect was in the opposite direction, percent of total effect was not calculated.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of total effect","timeFrame":"Over 12 weeks","groups":[{"id":"OG000","title":"Group B - Percent of Total Effect","description":"The percentage of the total treatment effect explained by the direct and indirect effects of treatment in the duloxetine 60 mg group."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"}]}],"classes":[{"title":"Direct Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"35.17"}]}]},{"title":"Indirect Treatment Effect from BPOMS Total Score","categories":[{"measurements":[{"groupId":"OG000","value":"64.83"}]}]},{"title":"Total Treatment Effect","categories":[{"measurements":[{"groupId":"OG000","value":"100.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in 16-Item Quick Inventory of Depressive Symptomatology Self Report (QIDS16SR) Total Score","description":"A 16-item patient-rated measure of depressive symptomatology. The total score ranges from 0 to 27 with higher scores indicative of greater severity.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"194"},{"groupId":"OG003","value":"62"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-6.31","spread":"0.34"},{"groupId":"OG001","value":"-5.65","spread":"0.55"},{"groupId":"OG002","value":"-6.54","spread":"0.33"},{"groupId":"OG003","value":"-5.21","spread":"0.52"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.41","spread":"0.77"},{"groupId":"OG001","value":"-6.85","spread":"1.36"},{"groupId":"OG002","value":"-7.17","spread":"0.59"},{"groupId":"OG003","value":"-6.15","spread":"1.11"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.302","pValueComment":"P-value for 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.029","pValueComment":"P-value for 12 Week Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.325","pValueComment":"P-value for 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.423","pValueComment":"P-value for 9 Month Change. Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Probability of Remission at 12 Week Endpoint and Sustained Remission at 9 Month Endpoint","description":"Probability of remission as measured by the HAMD17 Total Score ≤ 7 and by the QIDS16SR Total Score ≤ 5. The visitwise percentages of patients meeting criteria in the Acute Therapy Phase for remission (visitwise binary outcome, yes/no) will be analyzed using a categorical, pseudo-likelihood-based repeated measures approach. This analysis will include the fixed, categorical effects of treatment, investigator, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline score.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"probability of remission","timeFrame":"12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week HAMD-17 Total (n=194,n=59,n=195,n=64)","categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.21"},{"groupId":"OG001","value":"0.35","spread":"0.31"},{"groupId":"OG002","value":"0.35","spread":"0.19"},{"groupId":"OG003","value":"0.18","spread":"0.34"}]}]},{"title":"12 Week QIDS16 Total Score (n=194,n=58,n=194,n=62)","categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.19"},{"groupId":"OG001","value":"0.30","spread":"0.30"},{"groupId":"OG002","value":"0.33","spread":"0.17"},{"groupId":"OG003","value":"0.19","spread":"0.30"}]}]},{"title":"9 Month HAMD-17 Total Score (n=29,n=9,n=33,n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.35"},{"groupId":"OG001","value":"0.62","spread":"0.63"},{"groupId":"OG002","value":"0.70","spread":"0.36"},{"groupId":"OG003","value":"0.57","spread":"0.65"}]}]},{"title":"9 Month QIDS16 Total Score (n=29,n=9,n=33,n=9)","categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.31"},{"groupId":"OG001","value":"0.54","spread":"0.51"},{"groupId":"OG002","value":"0.71","spread":"0.35"},{"groupId":"OG003","value":"0.64","spread":"0.66"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.731","pValueComment":"P-value for 12 Week HAMD-17. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.022","pValueComment":"P-value for 12 Week HAMD-17. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.948","pValueComment":"P-value for 12 Week QIDS16. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.022","pValueComment":"P-value for 12 Week QIDS16. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.950","pValueComment":"P-value for 9 Month HAMD-17. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.442","pValueComment":"P-value for 9 Month HAMD-17. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.218","pValueComment":"P-value for 9 Month QIDS16. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.648","pValueComment":"P-value for 9 Month QIDS16. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Probability of Response at 12 Week Endpoint","description":"Probability of response as measured by ≥ 50% Improvement in the HAMD17 Total Score and ≥ 50% Improvement in the QIDS16SR Total Score. The visitwise percentages of patients meeting criteria in the Acute Therapy Phase for response (visitwise binary outcome, yes/no) will be analyzed using a categorical, pseudo-likelihood-based repeated measures approach. This analysis will include the fixed, categorical effects of treatment, investigator, visit, and treatment-by-visit interaction, as well as the continuous, fixed covariate of baseline score.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"probability of response","timeFrame":"12 weeks","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"HAMD-17 Total Score (n=194,n=59,n=195,n=64)","categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.16"},{"groupId":"OG001","value":"0.60","spread":"0.27"},{"groupId":"OG002","value":"0.63","spread":"0.16"},{"groupId":"OG003","value":"0.46","spread":"0.26"}]}]},{"title":"QIDS16 Total Score (n=194,n=58,n=194,n=62)","categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.15"},{"groupId":"OG001","value":"0.41","spread":"0.26"},{"groupId":"OG002","value":"0.45","spread":"0.16"},{"groupId":"OG003","value":"0.34","spread":"0.26"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.653","pValueComment":"P-value for 12 week HAMD-17. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.016","pValueComment":"P-value for 12 week HAMD-17. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.665","pValueComment":"P-value for 12 week QIDS16. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.127","pValueComment":"P-value for 12 week QIDS16. Model=Baseline, Pooled Investigator, Visit, Treatment, and Treatment\\*Visit.","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in Pain Numerical Rating Scale (NRS)","description":"Item 1=Average musculoskeletal pain severity over the last week as measured by an 11-point Likert scale. Scores range from 0 (no pain) to 10 (worst possible pain). Item 7=How much they have been bothered by pain over the last week. Scores range from 0 (not bothered at all)to 10 (extremely bothered).","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"193"},{"groupId":"OG003","value":"63"}]}],"classes":[{"title":"Item 1 - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"0.16"},{"groupId":"OG001","value":"-1.35","spread":"0.26"},{"groupId":"OG002","value":"-0.96","spread":"0.18"},{"groupId":"OG003","value":"-1.16","spread":"0.30"}]}]},{"title":"Item 7 - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":"0.17"},{"groupId":"OG001","value":"-1.73","spread":"0.27"},{"groupId":"OG002","value":"-1.14","spread":"0.18"},{"groupId":"OG003","value":"-1.36","spread":"0.30"}]}]},{"title":"Item 1 - 9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":"0.41"},{"groupId":"OG001","value":"-0.10","spread":"0.73"},{"groupId":"OG002","value":"-2.10","spread":"0.41"},{"groupId":"OG003","value":"-2.36","spread":"0.75"}]}]},{"title":"Item 7 - 9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.56","spread":"0.42"},{"groupId":"OG001","value":"-0.42","spread":"0.74"},{"groupId":"OG002","value":"-2.24","spread":"0.35"},{"groupId":"OG003","value":"-2.11","spread":"0.64"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.475","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 1 Average Pain Severity 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.561","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 1 Average Pain Severity 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.213","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 7 How Bothered by Pain 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.536","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 7 How Bothered by Pain 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.158","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 1 Average Pain Severity 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.759","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 1 Average Pain Severity 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.190","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 7 How Bothered by Pain 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.852","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Item 7 How Bothered by Pain 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoint in the Clinical Global Impression-Severity Scale (CGI-S)","description":"Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"0.08"},{"groupId":"OG001","value":"-1.58","spread":"0.14"},{"groupId":"OG002","value":"-1.97","spread":"0.09"},{"groupId":"OG003","value":"-1.25","spread":"0.15"}]}]},{"title":"9 Month Change (n=29, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.14","spread":"0.22"},{"groupId":"OG001","value":"-1.97","spread":"0.40"},{"groupId":"OG002","value":"-2.61","spread":"0.21"},{"groupId":"OG003","value":"-2.23","spread":"0.37"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.032","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.705","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.388","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ)","description":"A 7-item patitent-rated questionnaire pertaining to a patient's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each of the 7 questions is scored on a 6-point scale ranging fom 1 (greater than normal) to 6 (totally absent). Total score ranges from 7 to 42.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"194"},{"groupId":"OG003","value":"64"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-7.60","spread":"0.46"},{"groupId":"OG001","value":"-6.39","spread":"0.74"},{"groupId":"OG002","value":"-7.96","spread":"0.47"},{"groupId":"OG003","value":"-6.85","spread":"0.74"}]}]},{"title":"9 Month Change (n=29, n=9, n=32, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.17","spread":"0.88"},{"groupId":"OG001","value":"-7.13","spread":"1.54"},{"groupId":"OG002","value":"-8.19","spread":"0.84"},{"groupId":"OG003","value":"-6.77","spread":"1.48"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.161","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.198","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.982","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.407","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in the Social Adaptation Self-evaluation Scale (SASS) Total Score","description":"A 21-item self-rated scale that evaluates patient social motivation and behavior in depression. Each of the 21 items is scored from 0 (minimal social adjustment) to 3 (maximal social adjustment). Total score ranges from 0 to 60.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"185"},{"groupId":"OG003","value":"62"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"7.18","spread":"0.62"},{"groupId":"OG001","value":"3.40","spread":"0.99"},{"groupId":"OG002","value":"7.54","spread":"0.61"},{"groupId":"OG003","value":"4.52","spread":"0.92"}]}]},{"title":"9 Month Change (n=28, n=9, n=30, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"8.00","spread":"1.14"},{"groupId":"OG001","value":"5.30","spread":"1.92"},{"groupId":"OG002","value":"13.81","spread":"1.04"},{"groupId":"OG003","value":"9.28","spread":"1.92"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.231","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.040","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in Blood Pressure","description":"Sitting systolic and diastolic blood pressure.","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mm Hg","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"196"},{"groupId":"OG003","value":"63"}]}],"classes":[{"title":"Systolic Blood Pressure (SBP) - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.78"},{"groupId":"OG001","value":"0.05","spread":"1.33"},{"groupId":"OG002","value":"0.73","spread":"0.76"},{"groupId":"OG003","value":"-2.95","spread":"1.25"}]}]},{"title":"Diastolic Blood Pressure (DBP) - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.51"},{"groupId":"OG001","value":"-0.58","spread":"0.88"},{"groupId":"OG002","value":"1.97","spread":"0.61"},{"groupId":"OG003","value":"-0.50","spread":"1.00"}]}]},{"title":"SBP - 9 Month Change (n=28, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"2.31"},{"groupId":"OG001","value":"-0.44","spread":"4.02"},{"groupId":"OG002","value":"-2.22","spread":"1.63"},{"groupId":"OG003","value":"-0.54","spread":"2.91"}]}]},{"title":"DBP - 9 Month Change (n=28, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.25","spread":"1.25"},{"groupId":"OG001","value":"1.46","spread":"2.18"},{"groupId":"OG002","value":"-1.52","spread":"1.47"},{"groupId":"OG003","value":"-1.05","spread":"2.69"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.914","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Systolic Blood Pressure 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.011","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Systolic Blood Pressure 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.296","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Diastolic Blood Pressure 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.034","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Diastolic Blood Pressure 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.874","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Systolic Blood Pressure (SBP) 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.614","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Systolic Blood Pressure (SBP) 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.146","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Diastolic Blood Pressure (DBP) 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.877","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for Diastolic Blood Pressure (DBP) 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in Pulse Rate","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"beats per minute","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"196"},{"groupId":"OG003","value":"63"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"1.40","spread":"0.57"},{"groupId":"OG001","value":"-1.52","spread":"1.01"},{"groupId":"OG002","value":"0.68","spread":"0.70"},{"groupId":"OG003","value":"-2.05","spread":"1.18"}]}]},{"title":"9 Month Change (n=28, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"1.79"},{"groupId":"OG001","value":"-0.30","spread":"3.11"},{"groupId":"OG002","value":"1.18","spread":"1.17"},{"groupId":"OG003","value":"-3.04","spread":"2.05"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.012","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.045","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.701","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.081","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Week and 9 Month Endpoints in Weight","populationDescription":"Number of participants with non-missing data at baseline and post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilograms","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"195"},{"groupId":"OG003","value":"63"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.20"},{"groupId":"OG001","value":"0.38","spread":"0.31"},{"groupId":"OG002","value":"-0.38","spread":"0.20"},{"groupId":"OG003","value":"-0.23","spread":"0.30"}]}]},{"title":"9 Month Change (n=28, n=9, n=33, n=10)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"2.31"},{"groupId":"OG001","value":"-0.44","spread":"4.02"},{"groupId":"OG002","value":"-0.94","spread":"0.55"},{"groupId":"OG003","value":"0.06","spread":"1.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.013","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.672","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 12 Week Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.874","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.390","pValueComment":"Model: Change from baseline=Baseline, Pooled Investigator, Visit, Treatment, Treatment\\*Visit and Baseline\\*Visit. P-value for 9 Month Change (Change=Endpoint minus baseline).","statisticalMethod":"Mixed Models Analysis","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Abnormal Vital Signs at Anytime Over 12 Weeks","populationDescription":"Number of participants wtih a normal baseline and at least one post-baseline measurement.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"over 12 weeks","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"254"},{"groupId":"OG003","value":"128"}]}],"classes":[{"title":"Sitting Pulse Rate - High","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Gain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Loss","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Systolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Diastolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]}]},{"type":"SECONDARY","title":"Abnormal Vital Signs at Anytime Over 9 Months","populationDescription":"Number of participants with a normal baseline and at least oone post-baseline measurement.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"over 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"254"},{"groupId":"OG003","value":"128"}]}],"classes":[{"title":"Sitting Pulse - High","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Gain","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Loss","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Systolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Diastolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"}]}]}]},{"type":"SECONDARY","title":"Abnormal Vital Signs at 12 Week Endpoint","populationDescription":"Number of participants with a normal baseline and at least one post-baseline measurement.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"12 weeks","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"254"},{"groupId":"OG003","value":"128"}]}],"classes":[{"title":"Sitting Pulse Rate - High","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Gain","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Loss","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Systolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Diastolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"SECONDARY","title":"Abnormal Vital Signs at 9 Month Endpoint","populationDescription":"Number of participants with a normal baseline and at least one post-baseline measurement.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"120"},{"groupId":"OG002","value":"254"},{"groupId":"OG003","value":"128"}]}],"classes":[{"title":"Sitting Pulse - High","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Gain","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight - Loss","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Systolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sitting Diastolic Blood Pressure - High","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"SECONDARY","title":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Bilirubin, Creatinine, Uric Acid","populationDescription":"Number of participants with non-missing data at baseline and at least one post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"micromole per Liter","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"110"}]}],"classes":[{"title":"Bilirubin - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"4.09"},{"groupId":"OG001","value":"-0.19","spread":"3.63"},{"groupId":"OG002","value":"-0.51","spread":"3.92"},{"groupId":"OG003","value":"0.13","spread":"3.64"}]}]},{"title":"Creatinine - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-1.56","spread":"9.55"},{"groupId":"OG001","value":"-0.85","spread":"8.27"},{"groupId":"OG002","value":"-1.21","spread":"8.95"},{"groupId":"OG003","value":"0.82","spread":"7.85"}]}]},{"title":"Uric Acid - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-2.77","spread":"48.20"},{"groupId":"OG001","value":"5.74","spread":"41.92"},{"groupId":"OG002","value":"-12.36","spread":"46.02"},{"groupId":"OG003","value":"7.05","spread":"44.20"}]}]},{"title":"Bilirubin - 9 Month Change (n=193,n=60,n=202,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"4.04"},{"groupId":"OG001","value":"-0.12","spread":"2.94"},{"groupId":"OG002","value":"-0.56","spread":"3.77"},{"groupId":"OG003","value":"0.25","spread":"3.56"}]}]},{"title":"Uric Acid - 9 Month Change (n=193,n=60,n=202,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.11","spread":"48.77"},{"groupId":"OG001","value":"-2.25","spread":"42.59"},{"groupId":"OG002","value":"-8.66","spread":"47.85"},{"groupId":"OG003","value":"6.50","spread":"44.80"}]}]}],"analyses":[{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.046","pValueComment":"P-value for Bilirubin - 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.031","pValueComment":"P-value for Creatinine - 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"P-value for Uric Acid - 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.033","pValueComment":"P-value for Bilirubin - 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.013","pValueComment":"P-value for Uric Acid - 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Hematocrit","populationDescription":"Number of participants with non-missing data at baseline and at least one post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Proportion of 1.0","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"196"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"Hematocrit - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.03"},{"groupId":"OG001","value":"-0.01","spread":"0.03"},{"groupId":"OG002","value":"0.00","spread":"0.03"},{"groupId":"OG003","value":"-0.01","spread":"0.03"}]}]},{"title":"Hematocrit - 9 Month Change (n=194,n=59,=197,n=67)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.03"},{"groupId":"OG001","value":"-0.00","spread":"0.03"},{"groupId":"OG002","value":"0.00","spread":"0.03"},{"groupId":"OG003","value":"-0.01","spread":"0.03"}]}]}],"analyses":[{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.037","pValueComment":"P-value for Hematocrit - 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.029","pValueComment":"P-value for Hematocrit - 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Mean Cell Volume (MCV)","populationDescription":"Number of participants with non-missing data at baseline and at least one post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"femtoliter","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"196"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"MCV - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"2.85"},{"groupId":"OG001","value":"1.30","spread":"3.30"},{"groupId":"OG002","value":"0.71","spread":"3.23"},{"groupId":"OG003","value":"-0.47","spread":"3.18"}]}]},{"title":"MCV - 9 Month Change (n=194,n=59,n=197,n=67)","categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"2.90"},{"groupId":"OG001","value":"1.66","spread":"3.08"},{"groupId":"OG002","value":"0.88","spread":"3.36"},{"groupId":"OG003","value":"-0.31","spread":"3.48"}]}]}],"analyses":[{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.013","pValueComment":"P-value for MCV - 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.014","pValueComment":"P-value for MCV - 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Chloride, Urea Nitrogen, Cholesterol, Sodium","populationDescription":"Number of participants with non-missing data at baseline and at least one post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimole per Liter","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"202"},{"groupId":"OG003","value":"66"}]}],"classes":[{"title":"Chloride - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"2.85"},{"groupId":"OG001","value":"0.24","spread":"2.62"},{"groupId":"OG002","value":"-0.91","spread":"2.75"},{"groupId":"OG003","value":"-0.39","spread":"2.51"}]}]},{"title":"Urea Nitrogen - 12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"1.29"},{"groupId":"OG001","value":"0.26","spread":"1.04"},{"groupId":"OG002","value":"0.01","spread":"1.20"},{"groupId":"OG003","value":"0.15","spread":"1.38"}]}]},{"title":"Chloride - 9 Month Change (n=193,n=60,n=202,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"2.92"},{"groupId":"OG001","value":"0.54","spread":"2.44"},{"groupId":"OG002","value":"-0.82","spread":"2.71"},{"groupId":"OG003","value":"-0.31","spread":"2.40"}]}]},{"title":"Cholesterol - 9 Month (n=193,n=60,n=202,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.70"},{"groupId":"OG001","value":"-0.30","spread":"0.78"},{"groupId":"OG002","value":"0.04","spread":"0.75"},{"groupId":"OG003","value":"-0.08","spread":"0.51"}]}]},{"title":"Sodium - 9 Month Change (n=193,n=60,n=202,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.67","spread":"3.30"},{"groupId":"OG001","value":"-0.73","spread":"2.47"},{"groupId":"OG002","value":"-1.86","spread":"3.16"},{"groupId":"OG003","value":"-1.73","spread":"3.12"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.022","pValueComment":"P-value for Chloride - 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.044","pValueComment":"P-value for Urea Nitrogen - 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","pValueComment":"P-value for Chloride - 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.045","pValueComment":"P-value for Cholesterol - 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.043","pValueComment":"P-value for Sodium - 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Changes in Baseline to 12 Week and 9 Month Endpoints Laboratory Values - Platelet Count","populationDescription":"Number of participants with non-missing data at baseline and at least post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Billions per Liter","timeFrame":"Baseline, 12 weeks, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"193"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"12 Week Change","categories":[{"measurements":[{"groupId":"OG000","value":"8.11","spread":"37.00"},{"groupId":"OG001","value":"-7.10","spread":"38.83"},{"groupId":"OG002","value":"10.55","spread":"37.53"},{"groupId":"OG003","value":"12.02","spread":"51.41"}]}]},{"title":"9 Month Change (n=191, n=58, n=194, n=67)","categories":[{"measurements":[{"groupId":"OG000","value":"8.06","spread":"37.62"},{"groupId":"OG001","value":"-10.17","spread":"35.73"},{"groupId":"OG002","value":"5.96","spread":"39.44"},{"groupId":"OG003","value":"10.18","spread":"51.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.017","pValueComment":"P-value for 12 Week Change.","statisticalMethod":"ANOVA","ciPctValue":"95"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","pValueComment":"P-value for 9 Month Change.","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Alkaline Phosphatase","populationDescription":"Number of participants with non-missing data at baseline and at least one post baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units per Liter","timeFrame":"baseline, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"202"},{"groupId":"OG003","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"10.61"},{"groupId":"OG001","value":"-2.30","spread":"10.20"},{"groupId":"OG002","value":"0.23","spread":"10.94"},{"groupId":"OG003","value":"-3.75","spread":"8.19"}]}]}],"analyses":[{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.033","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Changes in Baseline to 9 Month Endpoint Laboratory Values - Hemoglobin","populationDescription":"Number of participants with non-missing data at baseline and at least one post-baseline visit.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimoles per Liter (iron)","timeFrame":"Baseline, 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"197"},{"groupId":"OG003","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.45"},{"groupId":"OG001","value":"-0.19","spread":"0.54"},{"groupId":"OG002","value":"-0.01","spread":"0.47"},{"groupId":"OG003","value":"-0.17","spread":"0.53"}]}]}],"analyses":[{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.045","statisticalMethod":"ANOVA","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Abnormal Laboratory Values at Anytime/12 Week Endpoint","description":"The number of participants with statistically significant abnormal lab values at anytime and at 12 week endpoint were the same.","populationDescription":"Number of participants with a normal baseline and at least one post-baseline measurement.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"over 3 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"201"},{"groupId":"OG003","value":"66"}]}],"classes":[{"title":"Lymphocytes - High (n=186,n=57,n=195,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Potassium - Low (n=191,n=57,n=201,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.041","pValueComment":"P-value for Lymphocytes - High.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.048","pValueComment":"P-value for Potassium - Low.","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Abnormal Laboratory Values at Anytime During 9 Months","populationDescription":"Number of participants with a normal baseline at at least one post-baseline measurement.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"over 9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"202"},{"groupId":"OG003","value":"67"}]}],"classes":[{"title":"Lymphocytes - High (n=189,n=59,n=196,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Potassium - Low (n=194,n=59,n=202,n=67)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.012","pValueComment":"P-value for Lymphocytes - High.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.049","pValueComment":"P-value for Potassium - Low.","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Statistically Significant Abnormal Laboratory Values at 9 Month Endpoint","populationDescription":"Number of participants with a normal baseline and at least one post-baseline measurement.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"9 months","groups":[{"id":"OG000","title":"Group A - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG001","title":"Group A - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG002","title":"Group B - Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG003","title":"Group B - Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"196"},{"groupId":"OG003","value":"66"}]}],"classes":[{"title":"Lymphocytes - High (n=189,n=59,n=196,n=66)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Hemoglobin - Low (n=184,n=54,n=184,n=63)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.012","pValueComment":"P-value for Lymphocytes - High.","statisticalMethod":"Fisher Exact","ciPctValue":"95"},{"groupIds":["OG002","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.038","pValueComment":"P-value for Hemoglobin - Low.","statisticalMethod":"Fisher Exact","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Summary of Adverse Events Leading to Discontinuation","populationDescription":"Number of randomized participants in each treatment group.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"over 9 months","groups":[{"id":"OG000","title":"Duloxetine (Not Escalated)","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which participants remained on duloxetine 60 mg QD, PO for 6 months."},{"id":"OG001","title":"Duloxetine (Escalated)","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which participants were increased to duloxetine 120 mg QD, PO for 6 months"},{"id":"OG002","title":"Placebo (Not Rescued)","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."},{"id":"OG003","title":"Placebo (Rescued)","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"271"},{"groupId":"OG002","value":"104"},{"groupId":"OG003","value":"154"}]}],"classes":[{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Dizziness","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Rash","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Suicide attempt","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Weight increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Abdominal pain lower","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Abnormal dreams","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Asthma","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Blood pressure increased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Completed suicide","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Constipation","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Crying","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Depression","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Diarrhoea","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Disturbance in attention","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Dry mouth","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Dysgeusia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Hepatic function abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Hernia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Hyperhidrosis","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Influenza","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Irritability","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Lower gastrointestinal haemorrhage","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Lower limb fracture","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Mania","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Migraine","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Muscular weakness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Non-cardiac chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Paranoia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Pregnancy","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Restlessness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Road traffic accident","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Ruptured cerebral aneurysm","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Pneumonia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Tremor","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Urinary hesitation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Urinary retention","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Wound infection staphylococcal","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Anorgasmia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Astigmatism","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Cardiac failure congestive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Depressive symptom","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Dyspepsia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Gamma-glutamyltransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Hepatic enzyme increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Libido decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Night sweats","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Myocardial infarction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Nightmare","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Palpitations","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Pruritus","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Sexual dysfunction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Somnolence","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Sedation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Duloxetine","description":"duloxetine 60 mg every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months","seriousNumAffected":18,"otherNumAffected":497},{"id":"EG001","title":"Placebo","description":"placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months as part of a rescue plan with pre-defined criteria (Patients meeting criteria will automatically be assigned to duloxetine 60 mg QD).","seriousNumAffected":14,"otherNumAffected":237}],"seriousEvents":[{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Biliary colic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Oesophageal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Wound infection staphylococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Endometrial cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Ruptured cerebral aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Status migrainosus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Ruptured ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Homicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":518},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":258}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":518},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":258}]}],"otherEvents":[{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":19,"numAtRisk":518},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":258}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":71,"numAffected":63,"numAtRisk":518},{"groupId":"EG001","numEvents":32,"numAffected":30,"numAtRisk":258}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":62,"numAtRisk":518},{"groupId":"EG001","numEvents":33,"numAffected":30,"numAtRisk":258}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":98,"numAffected":95,"numAtRisk":518},{"groupId":"EG001","numEvents":38,"numAffected":36,"numAtRisk":258}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":33,"numAtRisk":518},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":258}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":24,"numAtRisk":518},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":258}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":49,"numAffected":49,"numAtRisk":518},{"groupId":"EG001","numEvents":26,"numAffected":26,"numAtRisk":258}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":155,"numAffected":123,"numAtRisk":518},{"groupId":"EG001","numEvents":45,"numAffected":37,"numAtRisk":258}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":49,"numAtRisk":518},{"groupId":"EG001","numEvents":24,"numAffected":20,"numAtRisk":258}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":518},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":258}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":65,"numAtRisk":518},{"groupId":"EG001","numEvents":35,"numAffected":35,"numAtRisk":258}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":48,"numAffected":47,"numAtRisk":518},{"groupId":"EG001","numEvents":24,"numAffected":19,"numAtRisk":258}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":23,"numAtRisk":518},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":258}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":38,"numAtRisk":518},{"groupId":"EG001","numEvents":25,"numAffected":20,"numAtRisk":258}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":44,"numAtRisk":518},{"groupId":"EG001","numEvents":20,"numAffected":20,"numAtRisk":258}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":518},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":258}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":39,"numAtRisk":518},{"groupId":"EG001","numEvents":21,"numAffected":20,"numAtRisk":258}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":28,"numAtRisk":518},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":258}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":79,"numAtRisk":518},{"groupId":"EG001","numEvents":36,"numAffected":35,"numAtRisk":258}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":28,"numAtRisk":518},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":258}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":58,"numAtRisk":518},{"groupId":"EG001","numEvents":30,"numAffected":28,"numAtRisk":258}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":221,"numAffected":177,"numAtRisk":518},{"groupId":"EG001","numEvents":96,"numAffected":83,"numAtRisk":258}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":48,"numAtRisk":518},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":258}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":24,"numAtRisk":518},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":258}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":22,"numAtRisk":518},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":258}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (12.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":27,"numAtRisk":518},{"groupId":"EG001","numEvents":28,"numAffected":24,"numAtRisk":258}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":69,"numAtRisk":518},{"groupId":"EG001","numEvents":42,"numAffected":38,"numAtRisk":258}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":42,"numAtRisk":518},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":258}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (11.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":27,"numAtRisk":518},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":258}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":101,"numAffected":100,"numAtRisk":518},{"groupId":"EG001","numEvents":57,"numAffected":56,"numAtRisk":258}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068736","term":"Duloxetine Hydrochloride"}],"ancestors":[{"id":"D013876","term":"Thiophenes"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}